{
  "messages": [
    {
      "role": "system",
      "content": "You are Earnings Call Prep AI.\nYou assist equity analysts and financial journalists in preparing for upcoming earnings calls.\n\nYou analyse only the documents the user provides (e.g., annual reports, interim reports, 10-K/10-Q equivalents, 8-K earnings releases, investor presentations, transcripts).\nMaintain context across the entire conversation.\nUse British English.\nNever invent numbers, facts, or events.\n\n1. Core behaviours\n\nAnalyse all provided documents and extract material financial and narrative information.\n\nCentre your work on the current reporting period, defined by the most recent documents (typically an 8-K earnings release, call remarks, or current interim/annual filing).\n\nUse older documents only for contextual trends, historical comparisons, management behaviour, and continuity of narrative.\n\nDo not generate questions centred on older periods unless they are directly relevant to understanding the current period.\n\nMaintain continuity across all conversational turns.\n\n2. Conflict handling\n\nWhen documents contain inconsistencies:\n\nFlag the discrepancy clearly.\n\nPresent both values with explicit source references.\n\nDo not choose or assume which value is correct unless the documents provide explicit guidance.\n\n3. Forbidden actions (cannot-do boundaries)\n\nYou must not:\n\nProvide investment advice, trading recommendations, or price targets.\n\nUse external or historical data not contained in the provided documents.\n\nExtrapolate or create future guidance beyond what the company states.\n\nInfer outcomes without textual or numerical support.\n\nProceed with analysis when no documents are provided (see Section 4).\n\n4. When documents are missing or unclear\n\nIf no documents are provided, request them before proceeding.\nAcceptable types include:\n8-K earnings releases, press releases, investor presentations, annual/interim reports, earnings call transcripts.\n\nIf the user uploads documents from multiple companies, ask which company should be in scope for this thread.\n\nIf the request is broad (e.g., \u201chelp me prep\u201d), ask the user to confirm:\n\nObjective (analysis vs. question generation)\n\nCompany\n\nWhich documents define the current period\n\nDo not start analysis or generate question sets until these are clear.\n\n5. What you produce\nA. Document analysis\n\nWhen the user requests analysis (explicitly or implicitly), use this structure:\n\nDefault analysis template\n\nCurrent period anchor\n\nCompany, reporting period, and which documents define it\n\nHeadline results and drivers\n\nY/Y and Q/Q where applicable\n\nSegment and geographic performance\n\nMargins, costs, and efficiency\n\nCash flow, balance sheet, and liquidity\n\nGuidance and outlook\n\nGAAP vs non-GAAP clarity; assumptions if stated\n\nRisks and uncertainties\n\nLegal, regulatory, operational, accounting, competitive\n\nNotable changes vs prior commentary/filings\n\nOpen items and data gaps\n\nIncluding document references\n\nB. Earnings call questions\n\nGenerate a full set only when:\n\nthe user explicitly asks for questions, or\n\nthe user uploads documents without instructions\n\nDefault question set behaviour:\n\nProvide ~8 high-priority questions.\n\nGroup them by theme.\n\nFor each question, include:\n\nThe question\n\nWhy it matters (1\u20132 lines)\n\nSource reference(s)\n\nFocus questions strictly on the current reporting period, using older documents only as context.\n\n6. Follow-up behaviour\n\nTreat follow-up requests as continuations; expand or clarify previous points.\n\nDo not regenerate a full question set unless the user explicitly requests a new one.\n\nKeep the conversation anchored on the current period\u2019s disclosures and the forthcoming earnings call.\n\n7. Tone & style\n\nProfessional, concise, analytical.\n\nSuitable for financial professionals.\n\nUse structured headings and bullet points.\n\nMaintain neutrality; avoid promotional or adversarial tone.\n\n8. Output examples (for behavioural guidance)\nAnalysis snippet example\n\nCurrent period anchor: Q3 FY2024 per 8-K earnings release dated 24 Oct 2024; investor presentation slides 3\u201315.\nHeadline: Revenue +6% Y/Y (+2% Q/Q) to \u00a31,245m [8-K, p.2]. Growth driven by EMEA enterprise (+12% Y/Y) offsetting North America SMB (-4% Y/Y) [Slides 5, 8].\n\nQuestion example\n\nQuestion: Gross margin declined 120 bps Y/Y to 62.8% despite a richer software mix. Can you quantify the headwinds (freight, discounts, inventory charges) and indicate whether these persist into Q4?\nWhy it matters: Clarifies sustainability of margin pressure and the likely near-term trajectory.\nSource: 8-K earnings release, p.4; Investor presentation, slide 9."
    },
    {
      "role": "user",
      "content": "I'm a financial journalist covering healthcare, United Health have just circulated an Earnings Release ahead of their earnings call today, can you give me a list of questions for the call?\n\n\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549\n__________________________________________________________\nFORM 10-Q\n__________________________________________________________\n\u2612 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the quarterly period ended June 30, 2025\nor\n\u2610 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the transition period from _______ to _______\nCommission File Number: 1-10864\n__________________________________________________________\nUnitedHealth Group Incorporated\n(Exact name of registrant as specified in its charter)\n __________________________________________________________\nDelaware 41-1321939\n(State or other jurisdiction of\nincorporation or organization)\n(I.R.S. Employer\nIdentification No.)\n1 Health Drive\n55344\n655 New York Avenue NW\nEden Prairie, Minnesota Washington, DC 20001\n(Address of principal executive offices) (Zip Code) (Address of principal executive offices) (Zip Code)\n(800) 328-5979\n(Registrant\u2019s telephone number, including area code)\n_________________________________________________________\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class Trading Symbol(s) Name of each exchange on which registered\nCommon Stock, $.01 par value UNH New York Stock Exchange\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12\nmonths (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \u2612 No \u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\u00a7232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes \u2612 No \u2610\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth\ncompany. See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act\nLarge accelerated filer \u2612 Accelerated filer \u2610 Non-accelerated filer \u2610\nSmaller reporting company \u2610 Emerging growth company \u2610\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. \u2610\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \u2610 No \u2612\nAs of July 31, 2025, there were 905,673,625 shares of the registrant\u2019s Common Stock, $.01 par value per share, issued and outstanding.\nUNITEDHEALTH GROUP\nTable of Contents\nPage\nPart I. Financial Information\nItem 1. Financial Statements (unaudited) ......................................................................................................................... 1\nCondensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 ..................................... 1\nCondensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and\n2024 .................................................................................................................................................................\n2\nCondensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June\n30, 2025 and 2024............................................................................................................................................. 3\nCondensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30,\n2025 and 2024................................................................................................................................................... 4\nCondensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 .......... 6\nNotes to the Condensed Consolidated Financial Statements................................................................................ 7\n1. Basis of Presentation.................................................................................................................................... 7\n2. Investments ................................................................................................................................................. 8\n3. Fair Value .................................................................................................................................................... 10\n4. Medical Costs Payable................................................................................................................................. 11\n5. Short-Term Borrowings and Long-Term Debt............................................................................................ 12\n6. Dividends..................................................................................................................................................... 12\n7. Commitments and Contingencies................................................................................................................ 12\n8. Held for Sale ................................................................................................................................................ 13\n9. Segment Financial Information ................................................................................................................... 14\nItem 2. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations .............................. 16\nItem 3. Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 25\nItem 4. Controls and Procedures....................................................................................................................................... 25\nPart II. Other Information\nItem 1. Legal Proceedings ................................................................................................................................................ 26\nItem 1A. Risk Factors.......................................................................................................................................................... 26\nItem 2. Unregistered Sales of Equity Securities and Use of Proceeds.............................................................................. 26\nItem 5. Other Information................................................................................................................................................. 26\nItem 6. Exhibits................................................................................................................................................................. 27\nSignatures............................................................................................................................................................................... 28\nPART I\n ITEM 1. FINANCIAL STATEMENTS\nUnitedHealth Group\nCondensed Consolidated Balance Sheets\n(Unaudited)\n(in millions, except per share data)\nJune 30,\n2025\nDecember 31,\n2024\nAssets\nCurrent assets:\nCash and cash equivalents...................................................................................................................... $ 28,596 $ 25,312\nShort-term investments........................................................................................................................... 3,424 3,801\nAccounts receivable, net......................................................................................................................... 24,142 22,365\nOther current receivables, net................................................................................................................. 28,582 26,089\nPrepaid expenses and other current assets.............................................................................................. 8,955 8,212\nTotal current assets......................................................................................................................................... 93,699 85,779\nLong-term investments................................................................................................................................... 52,466 52,354\nProperty, equipment and capitalized software, net......................................................................................... 10,923 10,553\nGoodwill......................................................................................................................................................... 107,677 106,734\nOther intangible assets, net............................................................................................................................. 22,510 23,268\nOther assets..................................................................................................................................................... 21,298 19,590\nTotal assets.................................................................................................................................................... $ 308,573 $ 298,278\nLiabilities, redeemable noncontrolling interests and equity\nCurrent liabilities:\nMedical costs payable............................................................................................................................. $ 38,427 $ 34,224\nAccounts payable and accrued liabilities................................................................................................ 34,330 34,337\nShort-term borrowings and current maturities of long-term debt........................................................... 5,698 4,545\nUnearned revenues ................................................................................................................................. 3,032 3,317\nOther current liabilities........................................................................................................................... 29,294 27,346\nTotal current liabilities.................................................................................................................................... 110,781 103,769\nLong-term debt, less current maturities.......................................................................................................... 73,495 72,359\nDeferred income taxes.................................................................................................................................... 3,804 3,620\nOther liabilities............................................................................................................................................... 15,709 15,939\nTotal liabilities................................................................................................................................................ 203,789 195,687\nCommitments and contingencies (Note 7)\nRedeemable noncontrolling interests.............................................................................................................. 4,315 4,323\nEquity:\nPreferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding................... \u2014 \u2014\nCommon stock, $0.01 par value - 3,000 shares authorized; 905 and 915 issued and outstanding......... 9 9\nRetained earnings ................................................................................................................................... 97,250 96,036\nAccumulated other comprehensive loss................................................................................................. (2,535) (3,387)\nNonredeemable noncontrolling interests........................................................................................................ 5,745 5,610\nTotal equity..................................................................................................................................................... 100,469 98,268\nTotal liabilities, redeemable noncontrolling interests and equity............................................................ $ 308,573 $ 298,278\nSee Notes to the Condensed Consolidated Financial Statements\n1\nUnitedHealth Group\nCondensed Consolidated Statements of Operations\n(Unaudited)\nThree Months Ended\nJune 30,\nSix Months Ended\nJune 30,\n(in millions, except per share data) 2025 2024 2025 2024\nRevenues:\nPremiums......................................................................................................... $ 87,905 $ 76,897 $ 174,439 $ 154,885\nProducts........................................................................................................... 13,564 12,211 26,600 24,120\nServices............................................................................................................ 9,039 8,750 18,011 17,638\nInvestment and other income........................................................................... 1,108 997 2,141 2,008\nTotal revenues.......................................................................................................... 111,616 98,855 221,191 198,651\nOperating costs:\nMedical costs................................................................................................... 78,585 65,458 151,996 131,193\nOperating costs................................................................................................ 13,778 13,162 27,372 27,239\nCost of products sold ....................................................................................... 13,019 11,340 25,409 22,396\nDepreciation and amortization......................................................................... 1,084 1,020 2,145 2,017\nTotal operating costs................................................................................................ 106,466 90,980 206,922 182,845\nEarnings from operations..................................................................................... 5,150 7,875 14,269 15,806\nInterest expense ....................................................................................................... (1,027) (985) (2,025) (1,829)\nLoss on sale of subsidiary and subsidiaries held for sale ........................................ (41) (1,225) (56) (8,311)\nEarnings before income taxes............................................................................... 4,082 5,665 12,188 5,666\nProvision for income taxes...................................................................................... (510) (1,244) (2,142) (2,466)\nNet earnings............................................................................................................ 3,572 4,421 10,046 3,200\nEarnings attributable to noncontrolling interests..................................................... (166) (205) (348) (393)\nNet earnings attributable to UnitedHealth Group common shareholders....... $ 3,406 $ 4,216 $ 9,698 $ 2,807\nEarnings per share attributable to UnitedHealth Group common\nshareholders:......................................................................................................\nBasic ................................................................................................................ $ 3.76 $ 4.58 $ 10.66 $ 3.05\nDiluted ............................................................................................................. $ 3.74 $ 4.54 $ 10.61 $ 3.02\nBasic weighted-average number of common shares outstanding ..................... 907 921 910 921\nDilutive effect of common share equivalents....................................................... 3 7 4 8\nDiluted weighted-average number of common shares outstanding.................. 910 928 914 929\nAnti-dilutive shares excluded from the calculation of dilutive effect of common\nshare equivalents.................................................................................................. 13 8 10 7\nSee Notes to the Condensed Consolidated Financial Statements\n2\nUnitedHealth Group\nCondensed Consolidated Statements of Comprehensive Income\n(Unaudited)\nThree Months Ended\nJune 30,\nSix Months Ended\nJune 30,\n(in millions) 2025 2024 2025 2024\nNet earnings....................................................................................................................... $ 3,572 $ 4,421 $ 10,046 $ 3,200\nOther comprehensive income:\nGross unrealized gains (losses) on investment securities during the period............... 327 (75) 848 (365)\nIncome tax effect......................................................................................................... (75) 17 (194) 85\nTotal unrealized gains (losses), net of tax.............................................................. 252 (58) 654 (280)\nGross reclassification adjustment for net realized gains included in net earnings...... (17) (26) (27) (58)\nIncome tax effect......................................................................................................... 4 6 6 13\nTotal reclassification adjustment, net of tax ........................................................ (13) (20) (21) (45)\nForeign currency translation gains (losses) ................................................................ 131 8 219 (285)\nReclassification adjustment for translation losses included in net earnings............... \u2014 86 \u2014 4,214\nTotal foreign currency translation gains................................................................ 131 94 219 3,929\nOther comprehensive income ........................................................................................... 370 16 852 3,604\nComprehensive income....................................................................................................... 3,942 4,437 10,898 6,804\nComprehensive income attributable to noncontrolling interests ........................................ (166) (205) (348) (393)\nComprehensive income attributable to UnitedHealth Group common shareholders $ 3,776 $ 4,232 $ 10,550 $ 6,411\nSee Notes to the Condensed Consolidated Financial Statements\n3\nUnitedHealth Group\nCondensed Consolidated Statements of Changes in Equity\n(Unaudited)\nCommon Stock\nAdditional\nPaid-In\nCapital\nRetained\nEarnings\nAccumulated Other\nComprehensive Loss\nNonredeemable\nNoncontrolling\nInterests\nTotal\nEquity\nThree months ended June 30,\n(in millions) Shares Amount\nNet\nUnrealized\n(Losses)\nGains on\nInvestments\nForeign\nCurrency\nTranslation\n(Losses)\nGains\nBalance at March 31, 2025 ................ 910 $ 9 $ \u2014 $ 97,934 $ (1,832) $ (1,073) $ 5,773 $ 100,811\nNet earnings....................................... 3,406 149 3,555\nOther comprehensive income ............ 239 131 370\nIssuances of common stock, and\nrelated tax effects........................... 1 \u2014 196 196\nShare-based compensation................. 229 229\nCommon share repurchases............... (6) \u2014 (415) (2,090) (2,505)\nCash dividends paid on common\nshares ($2.21 per share) ................. (2,000) (2,000)\nRedeemable noncontrolling interests\nfair value and other adjustments.... (10) (10)\nAcquisition and other adjustments of\nnonredeemable noncontrolling\ninterests.......................................... (19) (19)\nDistribution to nonredeemable\nnoncontrolling interests.................. (158) (158)\nBalance at June 30, 2025 ................... 905 $ 9 $ \u2014 $ 97,250 $ (1,593) $ (942) $ 5,745 $ 100,469\nBalance at March 31, 2024 ................ 920 $ 9 $ \u2014 $ 90,118 $ (2,218) $ (1,221) $ 5,682 $ 92,370\nNet earnings....................................... 4,216 158 4,374\nOther comprehensive (loss) income... (78) 94 16\nIssuances of common stock, and\nrelated tax effects........................... 1 \u2014 196 196\nShare-based compensation................. 210 210\nCommon share repurchases............... \u2014 \u2014 3 1 4\nCash dividends paid on common\nshares ($2.10 per share) ................. (1,935) (1,935)\nRedeemable noncontrolling interests\nfair value and other adjustments.... (36) (36)\nAcquisition and other adjustments of\nnonredeemable noncontrolling\ninterests.......................................... (338) (338)\nDistribution to nonredeemable\nnoncontrolling interests.................. (185) (185)\nBalance at June 30, 2024 ................... 921 $ 9 $ 373 $ 92,400 $ (2,296) $ (1,127) $ 5,317 $ 94,676\nSee Notes to the Condensed Consolidated Financial Statements\n4\nUnitedHealth Group\nCondensed Consolidated Statements of Changes in Equity\n(Unaudited)\nCommon Stock\nAdditional\nPaid-In\nCapital\nRetained\nEarnings\nAccumulated Other\nComprehensive Loss\nNonredeemable\nNoncontrolling\nInterests\nTotal\nEquity\nSix months ended June 30,\n(in millions) Shares Amount\nNet\nUnrealized\n(Losses)\nGains on\nInvestments\nForeign\nCurrency\nTranslation\n(Losses)\nGains\nBalance at January 1, 2025 ................ 915 $ 9 $ \u2014 $ 96,036 $ (2,226) $ (1,161) $ 5,610 $ 98,268\nNet earnings....................................... 9,698 297 9,995\nOther comprehensive income ............ 633 219 852\nIssuances of common stock, and\nrelated tax effects........................... 2 \u2014 379 379\nShare-based compensation................. 591 591\nCommon share repurchases............... (12) \u2014 (955) (4,572) (5,527)\nCash dividends paid on common\nshares ($4.31 per share) ................. (3,912) (3,912)\nRedeemable noncontrolling interests\nfair value and other adjustments.... (15) (15)\nAcquisition and other adjustments of\nnonredeemable noncontrolling\ninterests.......................................... 175 175\nDistribution to nonredeemable\nnoncontrolling interests.................. (337) (337)\nBalance at June 30, 2025 ................... 905 $ 9 $ \u2014 $ 97,250 $ (1,593) $ (942) $ 5,745 $ 100,469\nBalance at January 1, 2024 ................ 924 $ 9 $ \u2014 $ 95,774 $ (1,971) $ (5,056) $ 5,665 $ 94,421\nNet earnings....................................... 2,807 307 3,114\nOther comprehensive (loss) income... (325) 3,929 3,604\nIssuances of common stock, and\nrelated tax effects........................... 3 \u2014 438 438\nShare-based compensation................. 562 562\nCommon share repurchases............... (6) \u2014 (571) (2,517) (3,088)\nCash dividends paid on common\nshares ($3.98 per share) ................. (3,664) (3,664)\nRedeemable noncontrolling interests\nfair value and other adjustments.... (56) (56)\nAcquisition and other adjustments of\nnonredeemable noncontrolling\ninterests.......................................... (319) (319)\nDistribution to nonredeemable\nnoncontrolling interests.................. (336) (336)\nBalance at June 30, 2024 ................... 921 $ 9 $ 373 $ 92,400 $ (2,296) $ (1,127) $ 5,317 $ 94,676\nSee Notes to the Condensed Consolidated Financial Statements\n5\nUnitedHealth Group\nCondensed Consolidated Statements of Cash Flows\n(Unaudited)\nSix Months Ended\nJune 30,\n(in millions) 2025 2024\nOperating activities\nNet earnings.............................................................................................................................................................. $ 10,046 $ 3,200\nNoncash items:\nDepreciation and amortization ......................................................................................................................... 2,145 2,017\nDeferred income taxes...................................................................................................................................... (87) (358)\nShare-based compensation ............................................................................................................................... 572 594\nLoss on sale of subsidiary and subsidiaries held for sale................................................................................. 56 8,311\nOther, net.......................................................................................................................................................... 127 459\nNet change in other operating items, net of effects from acquisitions and dispositions:\nAccounts receivable ......................................................................................................................................... (1,681) (2,471)\nOther assets ...................................................................................................................................................... (2,143) (4,121)\nMedical costs payable ...................................................................................................................................... 4,371 777\nAccounts payable and other liabilities ............................................................................................................. (480) 36\nUnearned revenues........................................................................................................................................... (282) (554)\nCash flows from operating activities........................................................................................................................ 12,644 7,890\nInvesting activities\nPurchases of investments ......................................................................................................................................... (8,180) (10,130)\nSales of investments................................................................................................................................................. 5,181 5,288\nMaturities of investments......................................................................................................................................... 4,326 4,621\nCash paid for acquisitions and other transactions, net of cash assumed.................................................................. (734) (3,031)\nPurchases of property, equipment and capitalized software .................................................................................... (1,784) (1,596)\nLoans to care providers - cyberattack ...................................................................................................................... \u2014 (8,100)\nRepayments of care provider loans - cyberattack .................................................................................................... 1,293 604\nOther, net.................................................................................................................................................................. (1,618) (1,413)\nCash flows used for investing activities................................................................................................................... (1,516) (13,757)\nFinancing activities\nCommon share repurchases...................................................................................................................................... (5,545) (3,072)\nCash dividends paid ................................................................................................................................................. (3,912) (3,664)\nProceeds from common stock issuances.................................................................................................................. 581 744\nRepayments of long-term debt................................................................................................................................. \u2014 (1,750)\n(Repayments of) proceeds from short-term borrowings, net ................................................................................... (1,403) 8,615\nProceeds from issuance of long-term debt............................................................................................................... 2,969 5,925\nCustomer funds administered................................................................................................................................... (25) 990\nOther, net.................................................................................................................................................................. (513) (753)\nCash flows (used for) from financing activities....................................................................................................... (7,848) 7,035\nEffect of exchange rate changes on cash and cash equivalents................................................................................ 29 (44)\nIncrease in cash and cash equivalents, including cash within businesses held for sale ................................... 3,309 1,124\nLess: net increase in cash within businesses held for sale ....................................................................................... (25) (265)\nNet increase in cash and cash equivalents................................................................................................................ 3,284 859\nCash and cash equivalents, beginning of period.................................................................................................. 25,312 25,427\nCash and cash equivalents, end of period ............................................................................................................ $ 28,596 $ 26,286\nSee Notes to the Condensed Consolidated Financial Statements\n6\nUnitedHealth Group\nNotes to the Condensed Consolidated Financial Statements\n(Unaudited)\n1. Basis of Presentation\nUnitedHealth Group Incorporated (individually and together with its subsidiaries, \u201cUnitedHealth Group\u201d and the \u201cCompany\u201d)\nis a health care and well-being company with a mission to help people live healthier lives and help make the health system work\nbetter for everyone. The Company\u2019s two distinct, yet complementary businesses \u2014 Optum and UnitedHealthcare \u2014 are\nworking to help build a modern, high-performing health system through improved access, affordability, outcomes and\nexperiences for the individuals and organizations the Company is privileged to serve.\nThe Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted\nAccounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end\ncondensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures\nrequired by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the\nCompany has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual\naudited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read\ntogether with the Consolidated Financial Statements and the Notes included in Part II, Item 8, \u201cFinancial Statements and\nSupplementary Data\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the\nSEC (2024 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments\nnecessary to present the interim financial statements fairly.\nUse of Estimates\nThese Condensed Consolidated Financial Statements include certain amounts based on the Company\u2019s best estimates and\njudgments. The Company\u2019s most significant estimates relate to estimates and judgments for medical costs payable and\ngoodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve\nmatters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is\nincluded in earnings in the period in which the estimate is adjusted.\nRevenues - Products and Services\nAs of June 30, 2025 and December 31, 2024, accounts receivable related to products and services were $9.8 billion and\n$9.9 billion, respectively. As of June 30, 2025, revenue expected to be recognized in any future year related to remaining\nperformance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less,\ncontracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance\nobligations, was $11.9 billion, of which approximately half is expected to be recognized in the next three years.\n7\n2. Investments\nA summary of debt securities by major security type is as follows:\n(in millions)\nAmortized\nCost\nGross\nUnrealized\nGains\nGross\nUnrealized\nLosses\nFair\nValue\nJune 30, 2025\nDebt securities - available-for-sale:\nU.S. government and agency obligations............................. $ 4,189 $ 3 $ (186) $ 4,006\nState and municipal obligations............................................ 7,234 7 (375) 6,866\nCorporate obligations ........................................................... 24,044 106 (735) 23,415\nU.S. agency mortgage-backed securities.............................. 10,341 8 (783) 9,566\nNon-U.S. agency mortgage-backed securities...................... 2,875 7 (127) 2,755\nTotal debt securities - available-for-sale ...................................... 48,683 131 (2,206) 46,608\nDebt securities - held-to-maturity:\nU.S. government and agency obligations............................. 448 1 (1) 448\nState and municipal obligations............................................ 26 \u2014 (3) 23\nCorporate obligations ........................................................... 19 \u2014 \u2014 19\nTotal debt securities - held-to-maturity......................................... 493 1 (4) 490\nTotal debt securities...................................................................... $ 49,176 $ 132 $ (2,210) $ 47,098\nDecember 31, 2024\nDebt securities - available-for-sale:\nU.S. government and agency obligations............................. $ 4,600 $ 1 $ (274) $ 4,327\nState and municipal obligations............................................ 7,357 2 (375) 6,984\nCorporate obligations ........................................................... 24,391 56 (1,140) 23,307\nU.S. agency mortgage-backed securities.............................. 10,577 1 (994) 9,584\nNon-U.S. agency mortgage-backed securities...................... 2,890 2 (175) 2,717\nTotal debt securities - available-for-sale ...................................... 49,815 62 (2,958) 46,919\nDebt securities - held-to-maturity:\nU.S. government and agency obligations............................. 444 \u2014 (2) 442\nState and municipal obligations............................................ 28 \u2014 (2) 26\nCorporate obligations ........................................................... 40 \u2014 \u2014 40\nTotal debt securities - held-to-maturity ........................................ 512 \u2014 (4) 508\nTotal debt securities...................................................................... $ 50,327 $ 62 $ (2,962) $ 47,427\nThe Company held $5.4 billion and $4.9 billion of equity securities as of June 30, 2025 and December 31, 2024, respectively.\nThe Company\u2019s investments in equity securities primarily consist of venture investments and employee savings plan related\ninvestments. Additionally, the Company\u2019s investments included $3.4 billion and $3.8 billion of equity method investments\nprimarily in operating businesses in the health care sector as of June 30, 2025 and December 31, 2024, respectively. The\nallowance for credit losses on held-to-maturity securities at June 30, 2025 and December 31, 2024 was not material.\n8\nThe amortized cost and fair value of debt securities as of June 30, 2025, by contractual maturity, were as follows:\nAvailable-for-Sale Held-to-Maturity\n(in millions)\nAmortized\nCost\nFair\nValue\nAmortized\nCost\nFair\nValue\nDue in one year or less ..................................................................................................... $ 3,530 $ 3,506 $ 319 $ 319\nDue after one year through five years .............................................................................. 14,415 14,106 152 152\nDue after five years through ten years.............................................................................. 11,983 11,485 5 5\nDue after ten years............................................................................................................ 5,539 5,190 17 14\nU.S. agency mortgage-backed securities.......................................................................... 10,341 9,566 \u2014 \u2014\nNon-U.S. agency mortgage-backed securities.................................................................. 2,875 2,755 \u2014 \u2014\nTotal debt securities.......................................................................................................... $ 48,683 $ 46,608 $ 493 $ 490\nThe fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that\nindividual securities have been in a continuous unrealized loss position were as follows:\nLess Than 12 Months 12 Months or Greater Total\n(in millions)\nFair\nValue\nGross\nUnrealized\nLosses\nFair\nValue\nGross\nUnrealized\nLosses\nFair\nValue\nGross\nUnrealized\nLosses\nJune 30, 2025\nDebt securities - available-for-sale:\nU.S. government and agency obligations.......... $ 1,377 $ (21) $ 1,833 $ (165) $ 3,210 $ (186)\nState and municipal obligations......................... 2,116 (93) 4,037 (282) 6,153 (375)\nCorporate obligations......................................... 4,988 (80) 10,214 (655) 15,202 (735)\nU.S. agency mortgage-backed securities........... 3,914 (110) 4,561 (673) 8,475 (783)\nNon-U.S. agency mortgage-backed securities... 300 (2) 1,636 (125) 1,936 (127)\nTotal debt securities - available-for-sale.................... $ 12,695 $ (306) $ 22,281 $ (1,900) $ 34,976 $ (2,206)\nDecember 31, 2024\nDebt securities - available-for-sale:\nU.S. government and agency obligations .......... $ 1,475 $ (51) $ 2,152 $ (223) $ 3,627 $ (274)\nState and municipal obligations......................... 2,593 (58) 4,085 (317) 6,678 (375)\nCorporate obligations......................................... 7,402 (213) 11,449 (927) 18,851 (1,140)\nU.S. agency mortgage-backed securities........... 4,791 (191) 4,674 (803) 9,465 (994)\nNon-U.S. agency mortgage-backed securities... 416 (5) 1,863 (170) 2,279 (175)\nTotal debt securities - available-for-sale.................... $ 16,677 $ (518) $ 24,223 $ (2,440) $ 40,900 $ (2,958)\nThe Company\u2019s unrealized losses from debt securities as of June 30, 2025 were generated from approximately 28,000 positions\nout of a total of 43,000 positions. The Company believes that it will timely collect the principal and interest due on its debt\nsecurities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate\nincreases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company\u2019s\nassessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt\nsecurities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company\nevaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit\ndeterioration since purchase. As of June 30, 2025, the Company did not have the intent to sell any of the available-for-sale debt\nsecurities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit\nlosses on available-for-sale debt securities at June 30, 2025 and December 31, 2024 was not material.\n9\n3. Fair Value\nCertain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values\ndisclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of\nthree levels of a hierarchy defined by GAAP.\nFor a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy\nclassification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in\nPart II, Item 8, \u201cFinancial Statements and Supplementary Data\u201d in the 2024 10-K.\nThe following table presents a summary of fair value measurements by level and carrying values for items measured at fair\nvalue on a recurring basis in the Condensed Consolidated Balance Sheets:\n(in millions)\nQuoted Prices\nin Active\nMarkets\n(Level 1)\nOther\nObservable\nInputs\n(Level 2)\nUnobservable\nInputs\n(Level 3)\nTotal\nFair and\nCarrying\nValue\nJune 30, 2025\nCash and cash equivalents.............................................................................. $ 23,299 $ 5,297 $ \u2014 $ 28,596\nDebt securities - available-for-sale:\nU.S. government and agency obligations............................................... 3,876 130 \u2014 4,006\nState and municipal obligations............................................................. \u2014 6,866 \u2014 6,866\nCorporate obligations............................................................................. \u2014 22,942 473 23,415\nU.S. agency mortgage-backed securities................................................ \u2014 9,566 \u2014 9,566\nNon-U.S. agency mortgage-backed securities....................................... \u2014 2,755 \u2014 2,755\nTotal debt securities - available-for-sale ........................................................ 3,876 42,259 473 46,608\nEquity securities............................................................................................. 1,879 213 207 2,299\nTotal assets at fair value................................................................................. $ 29,054 $ 47,769 $ 680 $ 77,503\nPercentage of total assets at fair value ........................................................... 37 % 62 % 1 % 100 %\nDecember 31, 2024\nCash and cash equivalents.............................................................................. $ 25,248 $ 64 $ \u2014 $ 25,312\nDebt securities - available-for-sale:\nU.S. government and agency obligations............................................... 4,194 133 \u2014 4,327\nState and municipal obligations............................................................. \u2014 6,984 \u2014 6,984\nCorporate obligations............................................................................. 29 22,841 437 23,307\nU.S. agency mortgage-backed securities................................................ \u2014 9,584 \u2014 9,584\nNon-U.S. agency mortgage-backed securities....................................... \u2014 2,717 \u2014 2,717\nTotal debt securities - available-for-sale ........................................................ 4,223 42,259 437 46,919\nEquity securities............................................................................................. 1,859 24 65 1,948\nTotal assets at fair value................................................................................. $ 31,330 $ 42,347 $ 502 $ 74,179\nPercentage of total assets at fair value ........................................................... 42 % 57 % 1 % 100 %\nThere were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2025 or 2024.\n10\nThe following table presents a summary of fair value measurements by level and carrying values for certain financial\ninstruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:\n(in millions)\nQuoted Prices\nin Active\nMarkets\n(Level 1)\nOther\nObservable\nInputs\n(Level 2)\nUnobservable\nInputs\n(Level 3)\nTotal\nFair\nValue\nTotal\nCarrying\nValue\nJune 30, 2025\nDebt securities - held-to-maturity ........................................ $ 466 $ 24 $ \u2014 $ 490 $ 493\nLong-term debt and other financing obligations.................. $ \u2014 $ 74,304 $ \u2014 $ 74,304 $ 79,193\nDecember 31, 2024\nDebt securities - held-to-maturity ........................................ $ 482 $ 26 $ \u2014 $ 508 $ 512\nLong-term debt and other financing obligations.................. $ \u2014 $ 70,565 $ \u2014 $ 70,565 $ 75,604\nNonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are\nsubject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets\nand liabilities within our South American operations held for sale as of June 30, 2025 were measured at the lower of carrying\nvalue or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price\nderived from Company-specific information and market conditions. There were no significant fair value adjustments for assets\nand liabilities recorded during the six months ended June 30, 2025 or 2024.\n4. Medical Costs Payable\nThe following table shows the components of the change in medical costs payable for the six months ended June 30:\n(in millions) 2025 2024\nMedical costs payable, beginning of period ........................................................................................................ $ 34,224 $ 32,395\nAcquisitions (dispositions), net ........................................................................................................................... \u2014 (687)\nReported medical costs:\nCurrent year................................................................................................................................................. 152,316 131,583\nPrior years.................................................................................................................................................... (320) (390)\nTotal reported medical costs................................................................................................................................ 151,996 131,193\nMedical payments:\nPayments for current year............................................................................................................................ (118,793) (102,288)\nPayments for prior years.............................................................................................................................. (28,998) (27,887)\nTotal medical payments....................................................................................................................................... (147,791) (130,175)\nLess: increase in medical costs payable included within businesses held for sale.............................................. (2) (179)\nMedical costs payable, end of period .................................................................................................................. $ 38,427 $ 32,547\nFor the six months ended June 30, 2025 and 2024, prior years\u2019 medical cost reserve development included no individual factors\nthat were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the\nCompany of $26.8 billion and $23.7 billion at June 30, 2025 and December 31, 2024, respectively.\n11\n5. Short-Term Borrowings and Long-Term Debt\nIn June 2025, the Company issued $3.0 billion of senior unsecured notes consisting of the following:\n(in millions, except percentages) Par Value\n4.4%, June 2028............................................................................................................................................................ $ 500\n4.65%, January 2031..................................................................................................................................................... 750\n5.3%, June 2035............................................................................................................................................................ 1,000\n5.95%, June 2055.......................................................................................................................................................... 750\nFor more information on the Company\u2019s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the\nConsolidated Financial Statements included in Part II, Item 8, \u201cFinancial Statements and Supplementary Data\u201d in the 2024 10-\nK.\n6. Dividends\nIn June 2025, the Company\u2019s Board of Directors increased the Company\u2019s quarterly cash dividend to shareholders to an annual\nrate of $8.84 compared to $8.40 per share, which the Company had paid since June 2024. Declaration and payment of future\nquarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions\nchange.\nThe following table provides details of the Company\u2019s dividend payments during the six months ended June 30, 2025:\nPayment Date Amount per Share Total Amount Paid\n(in millions)\nMarch 18 .................................................................................................................... $ 2.10 $ 1,912\nJune 24........................................................................................................................ 2.21 2,000\n7. Commitments and Contingencies\nPending Acquisitions\nAs of June 30, 2025, the Company had entered into agreements to acquire companies in the health care sector, subject to\nregulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions,\nexcluding the payoff of acquired indebtedness, was approximately $4 billion.\nLegal Matters\nThe Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits\nbrought by members, care providers, consumer advocacy organizations, customers, shareholders, and regulators, relating to the\nCompany\u2019s businesses, including management and administration of health benefit plans and other services. These matters\ninclude medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to\nhealth care benefits coverage and other business practices.\nThe Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of\ncosts resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where\nthe matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present\nnovel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the\nearly stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to\nestimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be\nincurred.\n12\nGovernment Investigations, Audits and Reviews\nThe Company has been involved or is currently involved in various governmental investigations, audits and reviews. These\ninclude routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services\n(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General (OIG),\nthe Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade\nCommission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the\nU.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the\nConsumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other\ngovernmental authorities. Similarly, the Company\u2019s international businesses are also subject to investigations, audits and\nreviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and\ninvestigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters\nand no assurance as to whether its business, financial condition or results of operations will be materially adversely affected.\nCertain of the Company\u2019s businesses have been reviewed or are currently under review, including for, among other matters,\ncompliance with coding and other requirements under the Medicare risk-adjustment model. CMS and OIG have selected certain\nof the Company\u2019s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and\nsupporting documentation maintained by health care providers and such audits may result in retrospective adjustments to\npayments made to the Company\u2019s health plans.\nOn February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the\nCompany and filed under seal by a whistleblower in 2011. The whistleblower\u2019s complaint, which was unsealed on February 15,\n2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. In March 2025, a\nSpecial Master appointed by the court issued a report recommending that the court enter summary judgment in the Company\u2019s\nfavor on all remaining claims. In April 2025, the DOJ filed a motion asking the court to reject the Special Master\u2019s report. The\nCompany cannot reasonably estimate the outcome which may result from this matter given its procedural status.\n8. Held for Sale\nThe Company\u2019s planned sales of its remaining South American operations are expected to close within the year, subject to\nregulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid\nexpenses and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.\nThe assets and liabilities of the held for sale disposal groups as of June 30, 2025, were as follows:\n(in millions)\nBusinesses\nHeld for Sale\nAssets\nCash and cash equivalents.................................................................................................................................................. $ 244\nAccounts receivable and other current assets..................................................................................................................... 674\nProperty, equipment and capitalized software ................................................................................................................... 719\nGoodwill and other intangible assets ................................................................................................................................. 442\nOther long-term assets........................................................................................................................................................ 292\nRemeasurement of assets of businesses held for sale to fair value less cost to sell(1)\n........................................................ (1,314)\nTotal assets.................................................................................................................................................................... $ 1,057\nLiabilities\nMedical costs payable ........................................................................................................................................................ $ 181\nAccounts payable and other current liabilities................................................................................................................... 368\nOther long-term liabilities.................................................................................................................................................. 436\nTotal liabilities.............................................................................................................................................................. $ 985\n(1) Includes the effect of $847 million of cumulative foreign currency translation losses and $50 million of noncontrolling interests.\n13\n9. Segment Financial Information\nThe Company\u2019s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more\ninformation on the Company\u2019s segments, see Part I, Item I, \u201cBusiness\u201d and Note 14 of Notes to the Consolidated Financial\nStatements included in Part II, Item 8, \u201cFinancial Statements and Supplementary Data\u201d in the 2024 10-K.\nThe following tables present reportable segment financial information:\nOptum\n(in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx\nOptum\nEliminations Optum\nCorporate and\nEliminations Consolidated\nThree Months Ended June 30, 2025\nRevenues - unaffiliated customers:\nPremiums................................... $ 83,019 $ 4,886 $ \u2014 $ \u2014 $ \u2014 $ 4,886 $ \u2014 $ 87,905\nProducts..................................... \u2014 65 44 13,455 \u2014 13,564 \u2014 13,564\nServices...................................... 2,511 3,846 1,516 1,166 \u2014 6,528 \u2014 9,039\nTotal revenues - unaffiliated\ncustomers....................................... 85,530 8,797 1,560 14,621 \u2014 24,978 \u2014 110,508\nTotal revenues - affiliated customers. \u2014 15,953 3,236 23,790 (1,267) 41,712 (41,712) \u2014\nInvestment and other income............. 573 455 32 48 \u2014 535 \u2014 1,108\nTotal revenues.................................... $ 86,103 $ 25,205 $ 4,828 $ 38,459 $ (1,267) $ 67,225 $ (41,712) $ 111,616\nTotal operating costs (a).................... $ 84,028 $ 24,569 $ 3,830 $ 37,018 $ (1,267) $ 64,150 $ (41,712) $ 106,466\nEarnings from operations................... $ 2,075 $ 636 $ 998 $ 1,441 $ \u2014 $ 3,075 $ \u2014 $ 5,150\nInterest expense ................................. \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (1,027) (1,027)\nLoss on sale of subsidiary and\nsubsidiaries held for sale................ (41) \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (41)\nEarnings before income taxes............ $ 2,034 $ 636 $ 998 $ 1,441 $ \u2014 $ 3,075 $ (1,027) $ 4,082\nTotal assets ........................................ $ 129,587 $ 96,452 $ 33,716 $ 61,674 $ \u2014 $ 191,842 $ (12,856) $ 308,573\nPurchases of property, equipment\nand capitalized software ................ 193 306 289 98 \u2014 693 \u2014 886\nDepreciation and Amortization ......... 221 296 351 216 \u2014 863 \u2014 1,084\nThree Months Ended June 30, 2024\nRevenues - unaffiliated customers:\nPremiums................................... $ 70,950 $ 5,947 $ \u2014 $ \u2014 $ \u2014 $ 5,947 $ \u2014 $ 76,897\nProducts..................................... \u2014 62 41 12,108 \u2014 12,211 \u2014 12,211\nServices...................................... 2,388 4,083 1,405 874 \u2014 6,362 \u2014 8,750\nTotal revenues - unaffiliated\ncustomers....................................... 73,338 10,092 1,446 12,982 \u2014 24,520 \u2014 97,858\nTotal revenues - affiliated customers. \u2014 16,576 3,070 19,373 (1,129) 37,890 (37,890) \u2014\nInvestment and other income............. 528 382 27 60 \u2014 469 \u2014 997\nTotal revenues.................................... $ 73,866 $ 27,050 $ 4,543 $ 32,415 $ (1,129) $ 62,879 $ (37,890) $ 98,855\nTotal operating costs (a).................... $ 69,862 $ 25,131 $ 3,997 $ 31,009 $ (1,129) $ 59,008 $ (37,890) $ 90,980\nEarnings from operations................... $ 4,004 $ 1,919 $ 546 $ 1,406 $ \u2014 $ 3,871 $ \u2014 $ 7,875\nInterest expense ................................. \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (985) (985)\nLoss on sale of subsidiary and\nsubsidiaries held for sale................ (1,225) \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (1,225)\nEarnings before income taxes............ $ 2,779 $ 1,919 $ 546 $ 1,406 $ \u2014 $ 3,871 $ (985) $ 5,665\nTotal assets ........................................ $ 109,441 $ 93,858 $ 34,244 $ 56,058 $ \u2014 $ 184,160 $ (7,545) $ 286,056\nPurchases of property, equipment\nand capitalized software ................ 187 230 344 92 \u2014 666 \u2014 853\nDepreciation and Amortization ......... 221 277 316 206 \u2014 799 \u2014 1,020\n(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable\nfor each reportable segment.\n14\nOptum\n(in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx\nOptum\nEliminations Optum\nCorporate and\nEliminations Consolidated\nSix Months Ended June 30, 2025\nRevenues - unaffiliated customers:\nPremiums................................... $ 164,532 $ 9,907 $ \u2014 $ \u2014 $ \u2014 $ 9,907 $ \u2014 $ 174,439\nProducts..................................... \u2014 130 88 26,382 \u2014 26,600 \u2014 26,600\nServices...................................... 5,087 7,720 3,017 2,187 \u2014 12,924 \u2014 18,011\nTotal revenues - unaffiliated\ncustomers....................................... 169,619 17,757 3,105 28,569 \u2014 49,431 \u2014 219,050\nTotal revenues - affiliated customers. \u2014 31,867 6,298 44,927 (2,453) 80,639 (80,639) \u2014\nInvestment and other income............. 1,101 890 55 95 \u2014 1,040 \u2014 2,141\nTotal revenues.................................... $ 170,720 $ 50,514 $ 9,458 $ 73,591 $ (2,453) $ 131,110 $ (80,639) $ 221,191\nTotal operating costs (a).................... $ 163,419 $ 48,264 $ 7,499 $ 70,832 $ (2,453) $ 124,142 $ (80,639) $ 206,922\nEarnings from operations................... $ 7,301 $ 2,250 $ 1,959 $ 2,759 $ \u2014 $ 6,968 $ \u2014 $ 14,269\nInterest expense ................................. \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (2,025) (2,025)\nLoss on sale of subsidiary and\nsubsidiaries held for sale................ (56) \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (56)\nEarnings before income taxes............ $ 7,245 $ 2,250 $ 1,959 $ 2,759 $ \u2014 $ 6,968 $ (2,025) $ 12,188\nTotal assets ........................................ $ 129,587 $ 96,452 $ 33,716 $ 61,674 $ \u2014 $ 191,842 $ (12,856) $ 308,573\nPurchases of property, equipment\nand capitalized software ................ 389 585 627 183 \u2014 1,395 \u2014 1,784\nDepreciation and Amortization ......... 440 583 695 427 \u2014 1,705 \u2014 2,145\nSix Months Ended June 30, 2024\nRevenues - unaffiliated customers:\nPremiums................................... $ 143,243 $ 11,642 $ \u2014 $ \u2014 $ \u2014 $ 11,642 $ \u2014 $ 154,885\nProducts..................................... \u2014 121 82 23,917 \u2014 24,120 \u2014 24,120\nServices...................................... 4,917 8,053 3,107 1,561 \u2014 12,721 \u2014 17,638\nTotal revenues - unaffiliated\ncustomers....................................... 148,160 19,816 3,189 25,478 \u2014 48,483 \u2014 196,643\nTotal revenues - affiliated customers. \u2014 33,193 5,801 37,654 (2,145) 74,503 (74,503) \u2014\nInvestment and other income............. 1,063 772 55 118 \u2014 945 \u2014 2,008\nTotal revenues.................................... $ 149,223 $ 53,781 $ 9,045 $ 63,250 $ (2,145) $ 123,931 $ (74,503) $ 198,651\nTotal operating costs (a).................... $ 140,824 $ 49,963 $ 8,009 $ 60,697 $ (2,145) $ 116,524 $ (74,503) $ 182,845\nEarnings from operations................... $ 8,399 $ 3,818 $ 1,036 $ 2,553 $ \u2014 $ 7,407 $ \u2014 $ 15,806\nInterest expense ................................. \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (1,829) (1,829)\nLoss on sale of subsidiary and\nsubsidiaries held for sale................ (8,311) \u2014 \u2014 \u2014 \u2014 \u2014 \u2014 (8,311)\nEarnings before income taxes............ $ 88 $ 3,818 $ 1,036 $ 2,553 $ \u2014 $ 7,407 $ (1,829) $ 5,666\nTotal assets ........................................ $ 109,441 $ 93,858 $ 34,244 $ 56,058 $ \u2014 $ 184,160 $ (7,545) $ 286,056\nPurchases of property, equipment\nand capitalized software ................ 370 468 589 169 \u2014 1,226 \u2014 1,596\nDepreciation and Amortization ......... 456 549 626 386 \u2014 1,561 \u2014 2,017\n(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable\nfor each reportable segment.\n15\nITEM 2. MANAGEMENT\u2019S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS\nOF OPERATIONS\nThe following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and\nNotes and with our 2024 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,\n\u201cFinancial Statements and Supplementary Data\u201d in that report. Unless the context indicates otherwise, references to the terms\n\u201cUnitedHealth Group,\u201d the \u201cCompany,\u201d \u201cwe,\u201d \u201cour\u201d or \u201cus\u201d used throughout this Management\u2019s Discussion and Analysis of\nFinancial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.\nReaders are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and\nAnalysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic\nconditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and\nuncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking\nstatements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, \u201cRisk Factors\u201d in our 2024 10-K\nand in the discussion below.\nEXECUTIVE OVERVIEW\nGeneral\nUnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make\nthe health system work better for everyone. Our two distinct, yet complementary businesses \u2014 Optum and UnitedHealthcare \u2014\nare working to help build a modern, high-performing health system through improved access, affordability, outcomes and\nexperiences for the individuals and organizations we are privileged to serve.\nWe have four reportable segments:\n\u2022 Optum Health;\n\u2022 Optum Insight;\n\u2022 Optum Rx; and\n\u2022 UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement\nand UnitedHealthcare Community & State.\nFurther information on our business is presented in Part I, Item 1, \u201cBusiness\u201d and Part II, Item 7, \u201cManagement\u2019s Discussion\nand Analysis of Financial Condition and Results of Operations\u201d in our 2024 10-K and additional information on our segments\ncan be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item\n1 of this report.\nBusiness Trends\nOur businesses participate primarily in the United States health markets. We expect overall spending on health care to continue\nto grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements,\ndemographic trends in the population and national interest in health and well-being. The rate of market growth may be affected\nby a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of\noperations, including our continued efforts to control health care costs.\nPricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs,\nincluding medical care patterns, the mix and health status of people served, inflation and labor market dynamics. For 2025, our\npricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred,\nsignificantly impacting our earnings. We continually evaluate and adjust our approach in each of the local markets we serve,\nconsidering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and\nregulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We seek to\nbalance growth and profitability across all these dimensions.\nThe commercial risk market remains highly competitive in the small group, large group and individual segments. We expect\nbroad-based competition to continue as the industry adapts to individual and employer needs. Continued increased medical\ncosts may impact both future pricing and benefit design, including for our individual exchange products in markets we choose\nto remain, and result in shifts between product categories for our employer benefits. These potential changes, along with certain\nregulatory impacts, may result in decreased membership in future periods.\nMedicare Advantage funding continues to be pressured, as discussed below in \u201cRegulatory Trends and Uncertainties\u201d and we\nhave observed increased care patterns as discussed below in \u201cMedical Cost Trends,\u201d which may impact pricing and benefit\ndesign in future periods.\n16\nOptum Health\u2019s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have\nalso seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate.\nThe Medicaid redetermination process has caused a timing mismatch between the health status of people served through\nMedicaid and state rate updates. Due to elevated care activity, specifically related to behavioral, pharmacy and home health,\nthere continues to be a mismatch between the updated rates in 2025 and underlying member acuity. The funding and payment\nrate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure\non Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and\nmaintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost\ntrends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.\nAdditionally, we expect some Medicaid membership losses in 2026 as a result of early adoption of recent legislation.\nMedical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs.\nWe have observed increased care patterns, more notably related to physician and outpatient care, and to a lesser extent inpatient\nand emergency room utilization, that are above what we expected and contemplated in our pricing and benefits design. We have\nalso observed an increase in health care unit costs and the intensity of services delivered, driven by increases in provider pricing\nand additional services bundled per visit. Additionally, the member profile of newly added patients under value-based care\narrangements, people served in Medicare Advantage in markets where other plans exited, and peopled served within our\nindividual exchange business has contributed to increased medical costs. These trends may continue in future periods.\nThe Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in\nboth increased premiums and medical costs. The IRA also changed the quarterly relationship of medical costs to premiums,\naltering the seasonal progression and creating a more consistent relationship between medical costs and premiums throughout\nthe year.\nWe endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping\nthem make clinically sound choices, with the objective of helping them achieve high-quality, affordable care. Additionally, we\nhave elevated our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs.\nRegulatory Trends and Uncertainties\nMedicare Advantage Rates. Medicare Advantage rate notices for numerous years have resulted in industry base rates well\nbelow the industry forward medical cost trend, with the Final Notice for 2026 beginning to approach the industry forward\nmedical cost trend. Additionally, increased medical costs in 2025, which are significantly above initial cost trend estimates,\nadds to the compounding impact of the previous multi-year rate shortfalls creating sustained pressure on the Medicare\nAdvantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a\npatient\u2019s health status and care resource needs, have and will result in reduced funding and potentially benefits for people,\nespecially those with some of the greatest health and social challenges.\nAs a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures\nand reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make\nchanges to the size and composition of our care provider networks, adjust member benefits and implement or increase the\nmember premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on\na county-by-county basis where we will offer Medicare Advantage plans.\nSELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS\nThe following summarizes select second quarter 2025 year-over-year operating comparisons to second quarter 2024 and other\nfinancial results.\n\u2022 Consolidated revenues grew 13%, UnitedHealthcare revenues grew 17% and Optum revenues grew 7%.\n\u2022 UnitedHealthcare served 1.0 million more people, driven by growth in Medicare Advantage and commercial offerings.\n\u2022 Consolidated earnings from operations of $5.2 billion compared to $7.9 billion last year, with 2025 impacted by elevated\nmedical cost trend and 2024 impacted by the Change Healthcare cyberattack.\n\u2022 Diluted earnings per common share was $3.74.\n\u2022 Cash flows from operations for the six months ended June 30, 2025 were $12.6 billion.\n17\nRESULTS SUMMARY\nThe following table summarizes our consolidated results of operations and other financial information:\n(in millions, except percentages and per\nshare data)\nThree Months Ended\nJune 30,\nIncrease/\n(Decrease)\nSix Months Ended\nJune 30,\nIncrease/\n(Decrease)\n2025 2024 2025 vs. 2024 2025 2024 2025 vs. 2024\nRevenues:\nPremiums........................................... $ 87,905 $ 76,897 $ 11,008 14 % $ 174,439 $ 154,885 $ 19,554 13 %\nProducts............................................. 13,564 12,211 1,353 11 26,600 24,120 2,480 10\nServices............................................. 9,039 8,750 289 3 18,011 17,638 373 2\nInvestment and other income ............ 1,108 997 111 11 2,141 2,008 133 7\nTotal revenues........................................... 111,616 98,855 12,761 13 221,191 198,651 22,540 11\nOperating costs:\nMedical costs..................................... 78,585 65,458 13,127 20 151,996 131,193 20,803 16\nOperating costs.................................. 13,778 13,162 616 5 27,372 27,239 133 \u2014\nCost of products sold......................... 13,019 11,340 1,679 15 25,409 22,396 3,013 13\nDepreciation and amortization .......... 1,084 1,020 64 6 2,145 2,017 128 6\nTotal operating costs................................. 106,466 90,980 15,486 17 206,922 182,845 24,077 13\nEarnings from operations.......................... 5,150 7,875 (2,725) (35) 14,269 15,806 (1,537) (10)\nInterest expense......................................... (1,027) (985) (42) 4 (2,025) (1,829) (196) 11\nLoss on sale of subsidiary and\nsubsidiaries held for sale ....................... (41) (1,225) 1,184 (97) (56) (8,311) 8,255 (99)\nEarnings before income taxes ................... 4,082 5,665 (1,583) (28) 12,188 5,666 6,522 115\nProvision for income taxes........................ (510) (1,244) 734 (59) (2,142) (2,466) 324 (13)\nNet earnings............................................... 3,572 4,421 (849) (19) 10,046 3,200 6,846 214\nEarnings attributable to noncontrolling\ninterests.................................................. (166) (205) 39 (19) (348) (393) 45 (11)\nNet earnings attributable to UnitedHealth\nGroup common shareholders ................ $ 3,406 $ 4,216 $ (810) (19) % $ 9,698 $ 2,807 $ 6,891 245 %\nDiluted earnings per share attributable to\nUnitedHealth Group common\nshareholders .......................................... $ 3.74 $ 4.54 $ (0.80) $ 10.61 $ 3.02 $ 7.59\nMedical care ratio (a) ................................ 89.4 % 85.1 % 4.3 % 87.1 % 84.7 % 2.4 %\nOperating cost ratio ................................... 12.3 13.3 (1.0) 12.4 13.7 (1.3)\nOperating margin....................................... 4.6 8.0 (3.4) 6.5 8.0 (1.5)\nTax rate...................................................... 12.5 22.0 (9.5) 17.6 43.5 (25.9)\nNet earnings margin (b)............................. 3.1 4.3 (1.2) 4.4 1.4 3.0\nReturn on equity (c)................................... 14.4 % 19.2 % (4.8) 20.6 % 6.4 % 14.2\n\n(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.\n(b) Net earnings margin attributable to UnitedHealth Group shareholders.\n(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders\u2019\nequity. Average shareholders\u2019 equity is calculated using the shareholders\u2019 equity balance at the end of the preceding year and the shareholders\u2019 equity\nbalances at the end of each of the quarters in the year presented.\n18\n2025 RESULTS OF OPERATIONS COMPARED TO 2024 RESULTS OF OPERATIONS\nConsolidated Financial Results\nRevenues\nThe increases in revenues were primarily driven by growth in people served through Medicare Advantage and those with higher\nacuity needs within Medicaid, growth at Optum Rx and pricing trends.\nMedical Costs and MCR\nMedical costs increased primarily due to the IRA-driven impacts on Medicare Part D plans, elevated medical cost trend and\ngrowth in people served through Medicare Advantage and those with higher acuity needs. The MCR increased as a result of the\nrevenue effects of the Medicare funding reductions; elevated medical cost trend; the member profile of newly added patients\nunder value-based care arrangements; and the impacts of market morbidity changes on our individual exchange offerings,\nincluding the acceleration of anticipated future losses related to the second half of 2025; partially offset by the incremental\nmedical costs for accommodations made to care providers as a results of the Change Healthcare cyberattack incurred in 2024.\nFor the three months ended June 30, 2025, the MCR also increased due to the seasonal impacts of the IRA on Medicare Part D.\nOperating Cost Ratio\nThe operating cost ratio decreased primarily due to revenue impacts of government programs, including the IRA-driven impacts\non Medicare Part D plans, operating cost management and our direct response efforts to the Change Healthcare cyberattack\nincurred in 2024, partially offset by investments to support future growth.\nTax Rate\nThe effective income tax rate decreased due to tax benefits having significantly more impact due to lower pre-tax income in\n2025, taxable earnings mix and the impact of the updated full year effective tax rate expectation. For the six months ended June\n30, 2025, the tax rate was also lower due to non-deductible losses on the sale of subsidiary and subsidiaries held for sale in\n2024.\nReportable Segments\nSee Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more\ninformation on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people\nserved by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted\nscripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also\nallow management and investors to evaluate and understand business mix, including the level and scope of services provided to\npeople, and pricing trends when comparing the metrics to revenue by segment.\n19\nThe following table presents a summary of the reportable segment financial information:\nThree Months Ended\nJune 30,\nIncrease/\n(Decrease)\nSix Months Ended\n June 30,\nIncrease/\n(Decrease)\n(in millions, except percentages) 2025 2024 2025 vs. 2024 2025 2024 2025 vs. 2024\nRevenues\nUnitedHealthcare .......................... $ 86,103 $ 73,866 $ 12,237 17 % $ 170,720 $ 149,223 $ 21,497 14 %\nOptum Health........................ 25,205 27,050 (1,845) (7) 50,514 53,781 (3,267) (6)\nOptum Insight ....................... 4,828 4,543 285 6 9,458 9,045 413 5\nOptum Rx.............................. 38,459 32,415 6,044 19 73,591 63,250 10,341 16\nOptum eliminations............... (1,267) (1,129) (138) 12 (2,453) (2,145) (308) 14\nOptum ........................................... 67,225 62,879 4,346 7 131,110 123,931 7,179 6\nEliminations.................................. (41,712) (37,890) (3,822) 10 (80,639) (74,503) (6,136) 8\nConsolidated revenues.................. $ 111,616 $ 98,855 $ 12,761 13 % $ 221,191 $ 198,651 $ 22,540 11 %\nEarnings from operations\nUnitedHealthcare .......................... $ 2,075 $ 4,004 $ (1,929) (48) % $ 7,301 $ 8,399 $ (1,098) (13) %\nOptum Health........................ 636 1,919 (1,283) (67) 2,250 3,818 (1,568) (41)\nOptum Insight ....................... 998 546 452 83 1,959 1,036 923 89\nOptum Rx.............................. 1,441 1,406 35 2 2,759 2,553 206 8\nOptum ........................................... 3,075 3,871 (796) (21) 6,968 7,407 (439) (6)\nConsolidated earnings from\noperations.................................. $ 5,150 $ 7,875 $ (2,725) (35) % $ 14,269 $ 15,806 $ (1,537) (10) %\nOperating margin\nUnitedHealthcare .......................... 2.4 % 5.4 % (3.0) % 4.3 % 5.6 % (1.3) %\nOptum Health........................ 2.5 7.1 (4.6) 4.5 7.1 (2.6)\nOptum Insight ....................... 20.7 12.0 8.7 20.7 11.5 9.2\nOptum Rx.............................. 3.7 4.3 (0.6) 3.7 4.0 (0.3)\nOptum ........................................... 4.6 6.2 (1.6) 5.3 6.0 (0.7)\nConsolidated operating margin..... 4.6 % 8.0 % (3.4) % 6.5 % 8.0 % (1.5) %\nUnitedHealthcare\nThe following table summarizes UnitedHealthcare revenues by business:\nThree Months Ended\nJune 30,\nIncrease/\n(Decrease)\nSix Months Ended\nJune 30,\nIncrease/\n(Decrease)\n(in millions, except percentages) 2025 2024 2025 vs. 2024 2025 2024 2025 vs. 2024\nUnitedHealthcare Employer & Individual - Domestic... $ 18,950 $ 18,646 $ 304 2 % $ 38,016 $ 36,485 $ 1,531 4 %\nUnitedHealthcare Employer & Individual - Global ....... 819 591 228 39 1,601 2,123 (522) (25)\nUnitedHealthcare Employer & Individual - Total.. 19,769 19,237 532 3 39,617 38,608 1,009 3\nUnitedHealthcare Medicare & Retirement..................... 42,623 34,904 7,719 22 84,328 70,390 13,938 20\nUnitedHealthcare Community & State........................... 23,711 19,725 3,986 20 46,775 40,225 6,550 16\nTotal UnitedHealthcare revenues........................... $ 86,103 $ 73,866 $ 12,237 17 % $ 170,720 $ 149,223 $ 21,497 14 %\n20\nThe following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment\nand funding arrangement:\nJune 30, Increase/(Decrease)\n(in thousands, except percentages) 2025 2024 2025 vs. 2024\nCommercial:\nRisk-based................................................................................................................................. 8,440 8,735 (295) (3) %\nFee-based .................................................................................................................................. 21,530 20,835 695 3\nTotal Commercial ................................................................................................................... 29,970 29,570 400 1\nMedicare Advantage .................................................................................................................... 8,350 7,770 580 7\nMedicaid ...................................................................................................................................... 7,490 7,410 80 1\nMedicare Supplement (Standardized).......................................................................................... 4,305 4,335 (30) (1)\nTotal Community and Senior.................................................................................................. 20,145 19,515 630 3\nTotal UnitedHealthcare - Medical .......................................................................................... 50,115 49,085 1,030 2\nSupplemental Data:\nMedicare Part D stand-alone................................................................................................... 2,800 3,065 (265) (9) %\nSouth American businesses held for sale................................................................................ 1,165 1,330 (165) (12) %\nUnitedHealthcare\u2019s revenues increased due to the IRA-driven impacts on Medicare Part D plans and growth in the number of\npeople served through Medicare Advantage, fee-based commercial offerings and those with higher acuity needs, partially offset\nby decreased people served through risk-based commercial offerings. Earnings from operations decreased primarily due to the\nimpacts of Medicare Advantage funding reductions, elevated medical cost trend, the impacts of market morbidity changes on\nour individual exchange offerings, including the acceleration of anticipated future losses related to the second half of 2025 and\nother write-offs and settlements, partially offset by the incremental medical costs for accommodations to support care providers\nas a result of the Change Healthcare cyberattack incurred in 2024. For the six months ended June 30, 2025, decreased earnings\nfrom operations was also partially offset by the seasonal impact of the IRA on Medicare Part D.\nOptum\nTotal revenues increased primarily due to growth at Optum Rx, partially offset by Optum Health. Earnings from operations\ndecreased due to Optum Health, partially offset by the impacts of the Change Healthcare cyberattack incurred in 2024 and\nOptum Rx. The results by segment were as follows:\nOptum Health\nRevenues at Optum Health decreased primarily due to the conversion of risk-based contracts, Medicare Advantage funding\nreductions and the profile of members served, partially offset by growth in patients served under value-based arrangements.\nEarnings from operations decreased due to Medicare Advantage funding reductions, the member profile of newly added\npatients under value-based care arrangements, elevated medical cost trends and contractual settlements, partially offset by cost\nmanagement initiatives. For the six months ended June 30, 2025, decreased earnings from operations was also partially offset\nby the incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack\nincurred in 2024. Optum Health served approximately 98 million people and 104 million people as of June 30, 2025 and\nJune 30, 2024, respectively.\nOptum Insight\nRevenues at Optum Insight increased due to decreased business disruption impacts related to the Change Healthcare\ncyberattack. Earnings from operations at Optum Insight increased due to decreased business disruption impacts and direct\nresponse costs related to the Change Healthcare cyberattack.\nOptum Rx\nRevenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth\nin existing clients and growth in pharmacy services. Earnings from operations also increased due to operating cost efficiencies.\nOptum Rx fulfilled 414 million and 399 million adjusted scripts in the second quarters of 2025 and 2024, respectively.\n21\nLIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES\nLiquidity\nSummary of our Major Sources and Uses of Cash and Cash Equivalents\nSix Months Ended\nJune 30,\nIncrease/\n(Decrease)\n(in millions) 2025 2024 2025 vs. 2024\nSources of cash:\nCash provided by operating activities.......................................................................................... $ 12,644 $ 7,890 $ 4,754\nIssuances of short-term borrowings and long-term debt, net of repayments............................... 1,566 12,790 (11,224)\nProceeds from common stock issuances...................................................................................... 581 744 (163)\nCustomer funds administered ...................................................................................................... \u2014 990 (990)\nRepayments of care provider loans - cyberattack........................................................................ 1,293 604 689\nSales and maturities of investments, net of purchases................................................................. 1,327 \u2014 1,327\nTotal sources of cash............................................................................................................................ 17,411 23,018 (5,607)\nUses of cash:\nCommon stock repurchases......................................................................................................... (5,545) (3,072) (2,473)\nCash paid for acquisitions and other transactions, net of cash assumed...................................... (734) (3,031) 2,297\nPurchases of investments, net of sales of maturities.................................................................... \u2014 (221) 221\nPurchases of property, equipment and capitalized software........................................................ (1,784) (1,596) (188)\nCash dividends paid ..................................................................................................................... (3,912) (3,664) (248)\nLoans to care providers - cyberattack .......................................................................................... \u2014 (8,100) 8,100\nCustomer funds administered ...................................................................................................... (25) \u2014 (25)\nOther ............................................................................................................................................ (2,131) (2,166) 35\nTotal uses of cash................................................................................................................................. (14,131) (21,850) 7,719\nEffect of exchange rate changes on cash and cash equivalents........................................................... 29 (44) 73\nIncrease in cash and cash equivalents, including cash within businesses held for sale....................... $ 3,309 $ 1,124 $ 2,185\nLess: net increase in cash within businesses held for sale................................................................... (25) (265) 240\nNet increase in cash and cash equivalents........................................................................................... $ 3,284 $ 859 $ 2,425\n2025 Cash Flows Compared to 2024 Cash Flows\nIncreased cash flows provided by operating activities were driven by changes in working capital accounts, the seasonal impact\nof the IRA on Medicare Part D and the impacts of the Change Healthcare cyberattack incurred in 2024. Other significant\nchanges in sources or uses of cash year-over-year included net repayments of loans to care providers in response to the Change\nHealthcare cyberattack, decreased cash paid for acquisitions and increased net sales and maturities of investments, offset by\ndecreased net issuances of short-term borrowings and long-term debt, increased share repurchases and decreased customer\nfunds administered.\nFinancial Condition\nAs of June 30, 2025, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of\n$77.3 billion included approximately $28.6 billion of cash and cash equivalents (of which $3.3 billion was available for general\ncorporate use), $46.6 billion of debt securities and $2.1 billion of investments in marketable equity securities. Given the\nsignificant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair\nvalue of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities\nportfolio had a weighted-average duration of 4.3 years and a weighted-average credit rating of \u201cDouble A\u201d as of June 30, 2025.\nWhen multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the\nweighted-average credit rating.\n22\nCapital Resources and Uses of Liquidity\nIn addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital\nresources and uses of liquidity are as follows:\nCash Requirements. A summary of our cash requirements as of December 31, 2024 was disclosed in Part II, Item 7,\n\u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in our 2024 10-K. During the six\nmonths ended June 30, 2025, there were no material changes to this previously disclosed information outside the ordinary\ncourse of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We\ncontinually evaluate opportunities to expand our operations, including through internal development of new products, programs\nand technology applications and business combinations.\nShort-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing\nprogram, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for\ngeneral corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the\nConsolidated Financial Statements included in Part II, Item 8, \u201cFinancial Statements and Supplementary Data\u201d in our 2024 10-\nK.\nAs of June 30, 2025, we were in compliance with the various covenants under our bank credit facilities.\nLong-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to\nmeet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information\non our long-term debt, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of\nthis report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, \u201cFinancial Statements and\nSupplementary Data\u201d in our 2024 10-K.\nCredit Ratings. Our credit ratings as of June 30, 2025 were as follows:\nMoody\u2019s S&P Global Fitch A.M. Best\nRatings Outlook Ratings Outlook Ratings Outlook Ratings Outlook\nSenior unsecured debt.......................... A2 Negative A+ Negative A Stable A Negative\nCommercial paper................................ P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a\nThe availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating\ncash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic\nand market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase\nthe cost of borrowing for us or limit our access to capital.\nRegulatory Capital. As a result of an increased MCR impacting our regulated insurance and HMO subsidiaries, the specified\nlevels of required statutory capital required to be maintained are expected to increase. While we continue to maintain significant\nlevels of excess statutory capital in our subsidiaries, the amount of dividends our subsidiaries are able to pay to their parent\ncompanies during the remainder of 2025 may be impacted. During the six months ended June 30, 2025, our domestic insurance\nand HMO subsidiaries paid their parent companies dividends of $1.9 billion.\nShare Repurchase Program. During the six months ended June 30, 2025, we repurchased approximately 12.1 million shares at\nan average price of $454.82 per share. As of June 30, 2025, we had Board of Directors\u2019 authorization to purchase up to 21.0\nmillion shares of our common stock. The Board of Directors from time to time may further amend the share repurchase\nprogram in order to increase the authorized number of shares which may be repurchased under the program.\nDividends. In June 2025, our Board of Directors increased our quarterly cash dividend to an annual rate of $8.84 compared to\n$8.40 per share, which we had paid since June 2024. For more information on our dividend, see Note 6 of Notes to the\nCondensed Consolidated Financial Statements included in Part I, Item 1 of this report.\nPending Acquisitions. As of June 30, 2025, we have entered into agreements to acquire companies in the health care sector,\nsubject to regulatory approval and other customary closing conditions. The total anticipated consideration required for these\nacquisitions, excluding the payoff of acquired indebtedness, was approximately $4 billion.\nFor additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,\n\u201cFinancial Statements and Supplementary Data\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and\nResults of Operations\u201d included in Part II, Item 7 in our 2024 10-K.\n23\nRECENTLY ISSUED ACCOUNTING STANDARDS\nThere are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated\nFinancial Statements.\nCRITICAL ACCOUNTING ESTIMATES\nIn preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,\nwhich we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and\nestimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent\nliabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.\nOn an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,\nhowever, may materially differ from our calculated estimates, and this difference would be reported in our current operations.\nOur critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical\naccounting estimates, see \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d included\nin Part II, Item 7 in our 2024 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the\nConsolidated Financial Statements included in Part II, Item 8, \u201cFinancial Statements and Supplementary Data\u201d in our 2024 10-\nK.\nFORWARD-LOOKING STATEMENTS\nThe statements, estimates, projections, guidance or outlook contained in this document include \u201cforward-looking\u201d statements\nwhich are intended to take advantage of the \u201csafe harbor\u201d provisions of the federal securities laws. The words \u201cbelieve,\u201d\n\u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d and similar expressions identify\nforward-looking statements. These statements may contain information about financial prospects, economic conditions and\ntrends and involve risks and uncertainties. Actual results could differ materially from those that management expects,\ndepending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs;\nnew or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data\nsecurity incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received\nunder government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data\nvalidation audits; the DOJ\u2019s legal actions concerning our participation in the Medicare program; our ability to maintain and\nachieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if\nour technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy\ncare services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to\nour public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and\nmaintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of\npotential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government\ninvestigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties\nassociated with the sale of our remaining operations in South America; risks associated with public health crises arising from\nlarge-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and\nmanage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill\nand intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our\ncredit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our\nobligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend\npayment cycle, or continue repurchasing shares of our common stock.\nThis above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial\ncondition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.\nBy their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,\nuncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations\nexpressed or implied in this document or any of our prior communications. You should not place undue reliance on forwardlooking statements, which speak only as of the date they are made. We do not undertake to update or revise any forwardlooking statements, except as required by law.\n24\nITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK\nWe manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt\nacross maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of\ninterest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in\ncomprehensive income.\nThe following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%\npoint or 2% points as of June 30, 2025 on our investment income and interest expense per annum, and the fair value of our\ninvestments and debt (in millions, except percentages):\nJune 30, 2025\nIncrease (Decrease) in Market Interest Rate\nInvestment\nIncome Per\nAnnum\nInterest\nExpense Per\nAnnum\nFair Value of\nFinancial Assets\nFair Value of\nFinancial Liabilities\n2 %................................................................................... $ 734 $ 542 $ (4,202) $ (9,288)\n1........................................................................................ 367 271 (2,150) (5,058)\n(1)..................................................................................... (367) (256) 2,202 6,107\n(2)..................................................................................... (734) (510) 4,416 13,549\nNote: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on\nthe fair value of financial assets and liabilities as the rates are assumed to not fall below zero.\nITEM 4. CONTROLS AND PROCEDURES\nEVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES\nWe maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act\nof 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in\nreports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time\nperiods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal\nexecutive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.\nIn connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the\nparticipation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our\ndisclosure controls and procedures as of June 30, 2025. Based upon that evaluation, our Chief Executive Officer and Chief\nFinancial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of\nJune 30, 2025.\nCHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING\nThere have been no changes in our internal control over financial reporting during the quarter ended June 30, 2025 that have\nmaterially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\n25\nPART II. OTHER INFORMATION\nITEM 1. LEGAL PROCEEDINGS\nA description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed\nConsolidated Financial Statements included in Part I, Item 1 of this report.\nITEM 1A. RISK FACTORS\nIn addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item\n1A, \u201cRisk Factors\u201d of our 2024 10-K, which could materially affect our business, financial condition or future results. The risks\ndescribed in our 2024 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that\nwe currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.\nThere have been no material changes to the risk factors as disclosed in our 2024 10-K.\nITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS\nIssuer Purchases of Equity Securities (a)\nSecond Quarter 2025\nFor the Month Ended\nTotal Number of\nShares Purchased\nAverage Price Paid\nPer Share\nTotal Number of Shares\nPurchased as Part of\nPublicly Announced\nPlans or Programs\nMaximum Number of\nShares That May Yet Be\nPurchased Under The\nPlans or Programs\n(in millions) (in millions) (in millions)\nApril 30, 2025 ........................................ 3.8 $ 445.39 3.8 23.3\nMay 31, 2025 ......................................... 2.3 341.68 2.3 21.0\nJune 30, 2025 ......................................... \u2014 \u2014 \u2014 21.0\nTotal....................................................... 6.1 $ 407.06 6.1\n\n(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the\nBoard of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market\npurchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be\nrepurchased under the Board\u2019s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time\nto time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the\nprogram.\nITEM 5. OTHER INFORMATION\nTrading Arrangements\nDuring the quarter ended June 30, 2025, none of the Company\u2019s directors or officers (as defined in Rule 16a-1(f) under the\nExchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities\nintended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1\ntrading arrangement.\n26\nITEM 6. EXHIBITS**\nThe following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company\nfiles Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the\nSecurities Exchange Act of 1934 under Commission File No. 1-10864.\n3.1 Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the\nCompany\u2019s Registration Statement on Form 8-A/A filed on July 1, 2015)\n3.2 Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated\nby reference to Exhibit 3.2 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on\nFebruary 26, 2021)\n4.1 Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and\nWilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth\nGroup Incorporated\u2019s Current Report on Form 8-K filed on April 28, 2023)\n4.2 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National\nAssociation (incorporated by reference to Exhibit 4.1 to the Company\u2019s Registration Statement on Form S-3,\nSEC File Number 333-149031, filed on February 4, 2008)\n4.3 Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank\nTrust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated\nby reference to Exhibit 4.1 to UnitedHealth Group Incorporated\u2019s Current Report on Form 8-K filed on April\n24, 2023)\n*10.1 Employment Agreement, effective as of May 12, 2025, between United HealthCare Services, Inc. and Stephen\nHemsely\n31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\n32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\n101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its\nXBRL tags are embedded within the Inline XBRL document.\n101.SCH Inline XBRL Taxonomy Extension Schema Document.\n101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.\n101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.\n101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n 104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).\n ________________\n* Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed\npursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.\n** Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The\nCompany will furnish copies thereof to the SEC upon request.\n27\nSIGNATURES\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on\nits behalf by the undersigned thereunto duly authorized.\nUNITEDHEALTH GROUP INCORPORATED\n/s/ STEPHEN HEMSLEY Chair and Chief Executive Officer\n(principal executive officer)\nDated: August 11, 2025\nStephen Hemsley\n/s/ JOHN REX President and Chief Financial Officer\n(principal financial officer)\nDated: August 11, 2025\nJohn Rex\n/s/ THOMAS ROOS Senior Vice President and\nChief Accounting Officer\n(principal accounting officer)\nDated: August 11, 2025\nThomas Roos\n\n28\n\nPage 1 of 16\nUnitedHealth Group Re-Establishes Full Year Outlook\nand Reports Second Quarter 2025 Results\n\u2022 Full Year 2025 Revenue Outlook of $445.5 Billion to $448.0 Billion\n\u2022 Full Year 2025 Earnings Outlook of at least $14.65 Per Share, Adjusted Earnings of at least $16.00 Per Share\n\u2022 Second Quarter Earnings were $3.74 Per Share, Adjusted Earnings were $4.08 Per Share\n(July 29, 2025) UnitedHealth Group (NYSE: UNH) reported second quarter 2025 results and updated its 2025 outlook.\n\u201cUnitedHealth Group has embarked on a rigorous path back to being a high-performing company fully serving the health needs\nof individuals and society broadly,\u201d said Stephen Hemsley, chief executive officer of UnitedHealth Group. \u201cAs we strengthen\noperating disciplines, positioning us for growth in 2026 and beyond, the people at UnitedHealth Group will continue to support\nthe millions of patients, physicians and customers who rely on us, guided by a culture of service and longstanding values.\u201d\nOn May 13, 2025, UnitedHealth Group suspended its 2025 outlook. Today, UnitedHealth Group is updating its 2025 outlook,\nincluding revenues of $445.5 billion to $448.0 billion, net earnings of at least $14.65 per share and adjusted earnings of at least\n$16.00 per share. The new outlook reflects first half 2025 performance and expectations for the remainder of the year, including\nhigher realized and anticipated care trends. The company expects to return to earnings growth in 2026.\nOutlook components include:\nUnitedHealth Group 2025 Outlook ($ in millions, except per share data) Revenue Operating Earnings\nOptum $266,000 - $267,500 $12,550 - $12,850\nUnitedHealthcare $344,000 - $345,500 $9,000 - $9,300\nEliminations ($164,500) - ($165,000) -\nTotal UnitedHealth Group $445,500 - $448,000 $21,550 - $22,150\nDiluted Adjusted (a)\nNet Earnings per Share At least $14.65 At least $16.00\n(a) See page 15 of this release for a reconciliation of the non-GAAP measure.\nAdditional 2025 outlook tables can be found on pages 3, 5 and 9 of this release.\nThe company will provide additional details regarding current and planned actions on a teleconference for analysts and\ninvestors today at 8 a.m. ET. \nPage 2 of 16\nQuarterly Financial Performance\nThree Months Ended\nJune 30, June 30, March 31,\n2025 2024 2025\nRevenues $111.6 billion $98.9 billion $109.6 billion\nEarnings from Operations $5.2 billion $7.9 billion $9.1 billion\nNet Margin 3.1% 4.3% 5.7%\n\u2022 UnitedHealth Group\u2019s second quarter 2025 revenues grew $12.8 billion year-over-year to $111.6 billion, driven by growth\nwithin UnitedHealthcare and Optum.\n\u2022 Second quarter earnings from operations were $5.2 billion and adjusted net earnings were $4.08 per share. The second\nquarter results include $1.2 billion of unfavorable discrete impacts reflecting $620 million related to the individual\nexchange business, which includes the acceleration of future losses related to the second half of 2025, and several\nsettlement and other provisions.\n\u2022 The second quarter consolidated medical care ratio of 89.4% increased 430 basis points year-over-year. The increase was\nprimarily due to medical cost trends which significantly exceeded pricing trends, including both unit costs and the intensity\nof services delivered, and the ongoing effects of Medicare funding reductions. Medical reserve development was $70\nmillion unfavorable in the second quarter 2025, with nearly all related to 2025 dates of service. The full year 2025 medical\ncost ratio is now expected to be 89.25% +/- 25 basis points.\n\u2022 Days claims payable of 44.5 compared to 45.5 in the first quarter 2025 and 45.2 in second quarter 2024. The decline was\ndriven by the Medicare Part D program changes. Days sales outstanding declined 1.6 days year-over-year and 2.4 days\nsequentially on customer payment timing.\n\u2022 The second quarter 2025 operating cost ratio of 12.3% compared to 13.3% in the year ago quarter reflecting business mix,\ninclusive of the Part D program changes, reduced impacts from last year\u2019s Change Healthcare cyberattack and cost\nmanagement activities. The full year 2025 operating cost ratio is now expected to be 12.75% +/- 25 basis points.\n\u2022 The lower tax expense in the second quarter 2025 reflects the year-to-date impact of the updated full year effective tax rate\nexpectation. The full year 2025 tax rate is now expected to be ~18.5%, affected by the revised earnings outlook while the\nexpected tax benefit levels remain steady.\n\u2022 In June, the company increased its quarterly dividend rate by 5% to $2.21 and returned $4.5 billion to shareholders through\ndividends and share repurchases in the second quarter. UnitedHealth Group\u2019s annualized return on equity through the first\nsix months of 2025 was 20.6%, and the June 30, 2025 ratio of debt to total capital was 44.1%.\n\u2022 Cash flows from operations were $7.2 billion in second quarter 2025, or 2.0 times net income. \nPage 3 of 16\nUnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid\nbeneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and\nwellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.\nUnitedHealthcare 2025 Outlook\n($ in millions; membership in thousands)\nRevenues:\nEmployer & Individual $79,600 - $80,100\nMedicare & Retirement $170,200 - $170,700\nCommunity & State $94,200 - $94,700\nTotal UnitedHealthcare Revenue $344,000 - $345,500\nOperating Earnings $9,000 - $9,300\nOperating Margin 2.6% - 2.7%\nUnitedHealthcare People Served Growth in People Served Total People Served\nCommercial Risk (385) 8,460\nCommercial Fee 720 21,605\nTotal Commercial 335 30,065\nMedicare Advantage 650 8,495\nStandardized Medicare Supplement (50) 4,285\nMedicaid 200 7,635\nTotal Medical 1,135 50,480\nStand-Alone Part D Prescription Drug Plans (300) 2,750\n\u2022 Full year 2025 revenues for UnitedHealthcare are expected to range from $344.0 billion to $345.5 billion, growth of more\nthan 15% over 2024. Earnings from operations are expected to be in the range of $9.0 billion to $9.3 billion.\n\u2022 \u201cWhile we face challenges across our lines of business, we believe we can resolve these issues and recapture our earnings\ngrowth potential while ensuring people have access to high-quality, affordable health care,\u201d said Tim Noel,\nUnitedHealthcare chief executive officer.\n\u2022 The number of people served with medical benefits is expected to increase by up to 1.135 million over 2024, led by serving\nseniors and people with complex needs. The number of people served with commercial benefits is expected to increase by\nup to 335,000, with growth of 720,000 within self-funded employer-sponsored offerings. The number of people served\nwith commercial insured offerings is expected to decline by 385,000, comprised of 180,000 contraction in individual\ninsured offerings, of which 140,000 are on exchange products, and a decline of 205,000 in employer-sponsored group\nproducts. \nPage 4 of 16\nUnitedHealthcare Business Results - Continued\nQuarterly Financial Performance\nThree Months Ended\nJune 30, June 30, March 31,\n2025 2024 2025\nRevenues $86.1 billion $73.9 billion $84.6 billion\nEarnings from Operations $2.1 billion $4.0 billion $5.2 billion\nOperating Margin 2.4% 5.4% 6.2%\n\u2022 UnitedHealthcare\u2019s second quarter 2025 revenue of $86.1 billion grew $12.2 billion or 17% year-over-year.\nUnitedHealthcare served 50 million people in the second quarter 2025, an increase of 770,000 year-to-date.\n\u2013 UnitedHealthcare Employer & Individual second quarter 2025 revenues of $19.8 billion compared to $19.2\nbillion in second quarter 2024, with growth driven by commercial offerings. The number of people served increased\nby 400,000 year-over-year, with growth in employer self-funded offerings of 695,000 partially offset by attrition in\nboth individual and group fully-insured products.\n\u2013 UnitedHealthcare Medicare & Retirement second quarter 2025 revenues of $42.6 billion grew $7.7 billion or\n22% year-over-year due to Part D IRA impacts and growth in the number of people served. People served with\nindividual and group Medicare Advantage offerings grew 505,000 through the first half of 2025, while Medicare\nSupplement contracted by 30,000 through the first half of 2025 and Standalone Part D plans decreased by 250,000\nthrough the first half of 2025.\n\u2013 UnitedHealthcare Community & State second quarter 2025 revenues of $23.7 billion grew 20% year-over-year,\ndriven by growth in serving people with complex needs and Medicaid rate improvements. Members served grew by\n55,000 through the first half of 2025 to a total of 7.5 million people. The company now serves a total of 32 states\nand D.C.\n\u2022 Second quarter 2025 earnings from operations for UnitedHealthcare were $2.1 billion compared to $4.0 billion in second\nquarter 2024. Second quarter 2025 operating margin of 2.4% compared to 5.4% in second quarter 2024. This was primarily\ndue to higher-than-expected medical cost trend across the UnitedHealthcare businesses and the effects of the Medicare\nfunding reductions.\n\u2022 The higher medical trends are being driven by both an increase in units consumed and rapidly rising costs per patient\nencounter, which includes both the unit cost and the number, type and intensity of services being delivered having\nincreased well beyond the pricing and benefit design considerations established last year. For example, medical cost trend\nin Medicare Advantage offerings is expected to run at ~7.5% in 2025 compared to the 2025 pricing expectation of just over\n5%. The pricing and benefit designs for 2026 anticipate these trends to continue to accelerate meaningfully to nearly 10%.\nUnitedHealthcare is committed to providing high-quality, affordable health offerings for the people it serves and is working\nto deliver effective solutions in the current, unprecedented medical cost trend environment. \nPage 5 of 16\nThe Optum health services businesses serve the global health care marketplace, including payers, care providers, employers,\ngovernments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield\nclinical insights, Optum helps improve overall health system performance by optimizing care quality, reducing care costs and\nimproving the consumer experience.\nOptum 2025 Outlook ($ in millions) Revenues Operating Earnings Operating Margin\nOptum Health $101,100 - $101,600 $3,000 - $3,100 3.0% - 3.1%\nOptum Insight $19,000 - $19,500 $3,550 - $3,650 18.2% - 19.2%\nOptum Rx $151,000 - $151,500 $6,000 - $6,100 4.0%\nEliminations ($5,100)\nTotal Optum $266,000 - $267,500 $12,550 - $12,850 4.7% - 4.8%\nOptum Performance Metrics\nOptum Health Fully Accountable Value-Based Care Patients 5 million\nOptum Insight Revenue Backlog $32.0 billion\nOptum Rx Adjusted Scripts 1.67 billion\n\u2022 \u201cWe know Optum\u2019s performance has not met expectations. We are refocused on fundamental execution to ensure we meet\nour potential to help make the health system work better for everyone,\u201d said Dr. Patrick Conway, Optum chief executive\nofficer.\nOptum Health\n\u2022 Full year 2025 revenues for Optum Health are expected to be $101.1 billion to $101.6 billion, a decline of 4% over 2024.\nEarnings from operations are expected to be $3.0 billion to $3.1 billion. The full year operating earnings margin is\nestimated at 3.0% to 3.1%.\n\u2022 The number of patients served under fully accountable value-based care models is now expected to increase by ~300,000 to\n5 million. The company has intentionally reduced its planned 2025 expansion in new patients served from the initial\n650,000 view to 300,000 to better focus on the geographies, practices and clinicians with the most developed capabilities\nand to strengthen operational execution across the platform.\nOptum Insight\n\u2022 Full year 2025 Optum Insight revenues are expected to range from $19.0 billion to $19.5 billion compared to $18.8 billion\nin 2024. Earnings from operations are expected to be $3.55 billion to $3.65 billion. The full year operating earnings margin\nis estimated at 18.2% to 19.2% and the contract revenue backlog is expected to be $32.0 billion.\nOptum Rx\n\u2022 Full year 2025 Optum Rx revenues are expected to be $151.0 billion to $151.5 billion compared to $133.2 billion a year\nago, with the increase driven by continued strong growth in customers and people served across the company\u2019s integrated\npharmacy services offerings. Earnings from operations are expected to be $6.0 billion to $6.1 billion. The full year\noperating margin is estimated at 4.0% and adjusted scripts are expected to be 1.67 billion. \nPage 6 of 16\nOptum Business Results \u2013 Continued\nQuarterly Financial Performance\nThree Months Ended\nJune 30, June 30, March 31,\n2025 2024 2025\nRevenues $67.2 billion $62.9 billion $63.9 billion\nEarnings from Operations $3.1 billion $3.9 billion $3.9 billion\nOperating Margin 4.6% 6.2% 6.1%\nOptum Health\n\u2022 Optum Health\u2019s second quarter 2025 revenue of $25.2 billion decreased $1.8 billion or 7% year-over-year, driven by the\nlegacy customer contract revisions cited in first quarter 2025 and effects related to the Medicare Advantage funding cuts.\n\u2022 Second quarter earnings from operations were $636 million compared to $1.9 billion in the year ago quarter and operating\nmargins were 2.5% and 7.1%, respectively. The decline was due to higher medical care activity, the flow through effects\nfrom underpriced health plan offerings where the company assumes full risk, including the impacts of the Medicare\nfunding reductions and under-estimation of the V-28 risk model transition, and the mix of newly served patients.\nOptum Insight\n\u2022 Optum Insight\u2019s second quarter 2025 revenue of $4.8 billion increased 6% year-over-year driven by a diverse portfolio of\ntechnology and data driven offerings.\n\u2022 Second quarter earnings from operations were $998 million compared to $546 million a year ago and operating margins\nwere 20.7% and 12.0%, respectively, due to reduced impacts from the Change Healthcare cyberattack, a favorable mix of\nthe types of services and products being purchased by customers and improved operating efficiencies. The contract revenue\nbacklog was $32.1 billion.\nOptum Rx\n\u2022 Optum Rx\u2019s second quarter 2025 revenue of $38.5 billion increased 19% year-over-year driven by growth in new clients\nand expansion in existing client relationships.\n\u2022 Earnings from operations for second quarter 2025 were $1.4 billion compared to $1.4 billion a year ago and operating\nmargins were 3.7% and 4.3%, respectively. The operating margin decline year-over-year was primarily due to higher\nrevenue in the second quarter 2025 offset by increased fulfillment of high-cost drugs and the impact of the initial launch of\nthe private label business. Adjusted scripts grew to 414 million compared to 399 million last year. \nPage 7 of 16\nAbout UnitedHealth Group\nUnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives\nand help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers\ncare aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve\nbetter health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care\nexperience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow\nUnitedHealth Group on LinkedIn.\nEarnings Conference Call\nAs previously announced, UnitedHealth Group will discuss the company\u2019s results, strategy and future outlook on a conference\ncall with investors at 8:00 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from\nthe Investor Relations page of the company\u2019s website (www.unitedhealthgroup.com). Following the call, a webcast replay will\nbe on the Investor Relations page through August 12, 2025. This earnings release and the Form 8-K dated July 29, 2025, can\nalso be accessed from the Investor Relations page of the company\u2019s website.\nNon-GAAP Financial Information\nThis news release presents non-GAAP financial information provided as a complement to the results provided in accordance\nwith accounting principles generally accepted in the United States of America (\u201cGAAP\u201d). A reconciliation of the non-GAAP\nfinancial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at\nthe end of this release.\nForward-Looking Statements\nThe statements, estimates, projections, guidance or outlook contained in this document include \u201cforward-looking\u201d statements\nwhich are intended to take advantage of the \u201csafe harbor\u201d provisions of the federal securities laws. The words \u201cbelieve,\u201d\n\u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d and similar expressions identify\nforward-looking statements. These statements may contain information about financial prospects, economic conditions and\ntrends and involve risks and uncertainties. Actual results could differ materially from those that management expects,\ndepending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs;\nnew or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data\nsecurity incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received\nunder government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data\nvalidation audits; the DOJ\u2019s legal actions concerning our participation in the Medicare program; our ability to maintain and\nachieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if\nour technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy\ncare services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to\nour public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and\nmaintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of\npotential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government\ninvestigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties\nassociated with the sale of our remaining operations in South America; risks associated with public health crises arising from\nlarge-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and\nmanage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill\nand intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our\ncredit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our\nobligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend\npayment cycle, or continue repurchasing shares of our common stock.\nThis above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial\ncondition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.\nBy their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,\nuncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations\nexpressed or implied in this document or any of our prior communications. You should not place undue reliance on forwardlooking statements, which speak only as of the date they are made. We do not undertake to update or revise any forwardlooking statements, except as required by law.\nInvestors: Media:\ninvestor_relations@uhg.com uhgmedia@uhg.com\nUNITEDHEALTH GROUP\nEarnings Release Schedules and Supplementary Information\nQuarter Ended June 30, 2025\n\n\u2022 Supplemental Financial Information - 2025 Outlook\n\u2022 Condensed Consolidated Statements of Operations\n\u2022 Condensed Consolidated Balance Sheets\n\u2022 Condensed Consolidated Statements of Cash Flows\n\u2022 Supplemental Financial Information - Businesses\n\u2022 Supplemental Financial Information - People Served and Performance Metrics\n\u2022 Reconciliation of Non-GAAP Financial Measure\nPage 8 of 16\nUNITEDHEALTH GROUP\nSUPPLEMENTAL FINANCIAL INFORMATION - 2025 OUTLOOK\n($ and weighted-average shares in millions; except per share data)\nProjected Year Ended\nDecember 31, 2025\nRevenues:\nOptum ....................................................................................................................................................................................................... $266,000 - $267,500\nUnitedHealthcare.................................................................................................................................................................................... 344,000 - 345,500\nEliminations.............................................................................................................................................................................................. (164,500) - (165,000)\nTotal consolidated revenue............................................................................................................................................................... $445,500 - $448,000\nEarnings from operations:\nOptum ....................................................................................................................................................................................................... $12,550 - $12,850\nUnitedHealthcare.................................................................................................................................................................................... 9,000 - 9,300\nTotal consolidated operating earnings ............................................................................................................................................ $21,550 - $22,150\nInvestment and other income..................................................................................................................................................................... ~$4,400\nInterest expense........................................................................................................................................................................................... ~$4,200\nDepreciation and amortization................................................................................................................................................................... ~$4,300\nNet earnings attributable to UnitedHealth Group common shareholders........................................................................................... At least $13,350\nDiluted weighted-average shares outstanding........................................................................................................................................ 912 - 914\nDiluted earnings per share attributable to UnitedHealth Group common shareholders .................................................................. At least $14.65\nAdjusted earnings per share attributable to UnitedHealth Group common shareholders (a).......................................................... At least $16.00\nMedical care ratio......................................................................................................................................................................................... 89.25% +/- 25 bps\nOperating cost ratio..................................................................................................................................................................................... 12.75% +/- 25 bps\nOperating margin......................................................................................................................................................................................... 4.8% - 5.0%\nTax rate.......................................................................................................................................................................................................... ~18.5%\nCash flows from operations........................................................................................................................................................................ ~$16,000\n(a) See page 15 for a reconciliation of the non-GAAP measure.\nPage 9 of 16\nUNITEDHEALTH GROUP\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n(in millions, except per share data; unaudited)\nThree Months Ended\nJune 30,\nSix Months Ended\nJune 30,\n2025 2024 2025 2024\nRevenues\nPremiums ........................................................................................................................ $87,905 $76,897 $174,439 $154,885\nProducts........................................................................................................................... 13,564 12,211 26,600 24,120\nServices ........................................................................................................................... 9,039 8,750 18,011 17,638\nInvestment and other income....................................................................................... 1,108 997 2,141 2,008\n Total revenues........................................................................................................... 111,616 98,855 221,191 198,651\nOperating costs\nMedical costs .................................................................................................................. 78,585 65,458 151,996 131,193\nOperating costs .............................................................................................................. 13,778 13,162 27,372 27,239\nCost of products sold..................................................................................................... 13,019 11,340 25,409 22,396\nDepreciation and amortization..................................................................................... 1,084 1,020 2,145 2,017\n Total operating costs ................................................................................................ 106,466 90,980 206,922 182,845\nEarnings from operations.......................................................................................... 5,150 7,875 14,269 15,806\nInterest expense............................................................................................................. (1,027) (985) (2,025) (1,829)\nLoss on sale of subsidiary and subsidiaries held for sale........................................ (41) (1,225) (56) (8,311)\nEarnings before income taxes.................................................................................. 4,082 5,665 12,188 5,666\nProvision for income taxes............................................................................................ (510) (1,244) (2,142) (2,466)\nNet earnings.................................................................................................................. 3,572 4,421 10,046 3,200\nEarnings attributable to noncontrolling interests ....................................................... (166) (205) (348) (393)\nNet earnings attributable to UnitedHealth Group common shareholders.... $3,406 $4,216 $9,698 $2,807\nDiluted earnings per share attributable to UnitedHealth Group common\nshareholders ......................................................................................................... $3.74 $4.54 $10.61 $3.02\nAdjusted earnings per share attributable to UnitedHealth Group common\nshareholders (a).................................................................................................... $4.08 $6.80 $11.29 $13.71\nDiluted weighted-average common shares outstanding.......................................... 910 928 914 929\n(a) See page 15 for a reconciliation of the non-GAAP measure.\nPage 10 of 16\nUNITEDHEALTH GROUP\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in millions; unaudited)\nJune 30,\n2025\nDecember 31,\n2024\nAssets\nCash and short-term investments ..................................................................................................................................................... $32,020 $29,113\nAccounts receivable, net .................................................................................................................................................................... 24,142 22,365\nOther current assets............................................................................................................................................................................ 37,537 34,301\nTotal current assets................................................................................................................................................................... 93,699 85,779\nLong-term investments ....................................................................................................................................................................... 52,466 52,354\nOther long-term assets ....................................................................................................................................................................... 162,408 160,145\nTotal assets.................................................................................................................................................................................... $308,573 $298,278\nLiabilities, redeemable noncontrolling interests and equity\nMedical costs payable......................................................................................................................................................................... $38,427 $34,224\nShort-term borrowings and current maturities of long-term debt................................................................................................. 5,698 4,545\nOther current liabilities ........................................................................................................................................................................ 66,656 65,000\nTotal current liabilities............................................................................................................................................................... 110,781 103,769\nLong-term debt, less current maturities............................................................................................................................................ 73,495 72,359\nOther long-term liabilities.................................................................................................................................................................... 19,513 19,559\nRedeemable noncontrolling interests ............................................................................................................................................... 4,315 4,323\nEquity..................................................................................................................................................................................................... 100,469 98,268\nTotal liabilities, redeemable noncontrolling interests and equity........................................................................................... $308,573 $298,278\nPage 11 of 16\nUNITEDHEALTH GROUP\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in millions; unaudited)\nSix Months Ended\nJune 30,\n2025 2024\nOperating Activities\nNet earnings ......................................................................................................................................................................................... $10,046 $3,200\nNoncash items:\nDepreciation and amortization....................................................................................................................................................... 2,145 2,017\nDeferred income taxes and other.................................................................................................................................................. 40 101\nShare-based compensation ........................................................................................................................................................... 572 594\nLoss on sale of subsidiary and subsidiaries held for sale.......................................................................................................... 56 8,311\nNet changes in operating assets and liabilities............................................................................................................................... (215) (6,333)\nCash flows from operating activities.......................................................................................................................................... 12,644 7,890\nInvesting Activities\nSales and maturities of investments, net of purchases (purchases of investments, net of sales and maturities)............... 1,327 (221)\nPurchases of property, equipment and capitalized software........................................................................................................ (1,784) (1,596)\nCash paid for acquisitions and other transactions, net.................................................................................................................. (734) (3,031)\nLoans to care providers - cyberattack .............................................................................................................................................. \u2014 (8,100)\nRepayments of care provider loans - cyberattack.......................................................................................................................... 1,293 604\nOther, net .............................................................................................................................................................................................. (1,618) (1,413)\nCash flows used for investing activities .................................................................................................................................... (1,516) (13,757)\nFinancing Activities\nCommon share repurchases.............................................................................................................................................................. (5,545) (3,072)\nDividends paid...................................................................................................................................................................................... (3,912) (3,664)\nNet change in short-term borrowings and long-term debt............................................................................................................. 1,566 12,790\nOther, net .............................................................................................................................................................................................. 43 981\nCash flows (used for) from financing activities ........................................................................................................................ (7,848) 7,035\nEffect of exchange rate changes on cash and cash equivalents................................................................................................. 29 (44)\nIncrease in cash and cash equivalents, including cash within businesses held for sale......................................................... 3,309 1,124\nLess: net increase in cash within businesses held for sale .......................................................................................................... (25) (265)\nNet increase in cash and cash equivalents ..................................................................................................................................... 3,284 859\nCash and cash equivalents, beginning of period............................................................................................................................ 25,312 25,427\nCash and cash equivalents, end of period ...................................................................................................................................... $28,596 $26,286\nPage 12 of 16\nUNITEDHEALTH GROUP\nSUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES\n(in millions, except percentages)\n(unaudited)\nThree Months Ended\nJune 30,\nSix Months Ended\nJune 30,\n2025 2024 2025 2024\nRevenues\nUnitedHealthcare............................................................................................................ $86,103 $73,866 $170,720 $149,223\nOptum ............................................................................................................................... 67,225 62,879 131,110 123,931\nEliminations...................................................................................................................... (41,712) (37,890) (80,639) (74,503)\nTotal consolidated revenues................................................................................... $111,616 $98,855 $221,191 $198,651\nEarnings from Operations\nUnitedHealthcare............................................................................................................ $2,075 $4,004 $7,301 $8,399\nOptum (a) ......................................................................................................................... 3,075 3,871 6,968 7,407\nTotal consolidated earnings from operations....................................................... $5,150 $7,875 $14,269 $15,806\nOperating Margin\nUnitedHealthcare............................................................................................................ 2.4% 5.4% 4.3% 5.6%\nOptum ............................................................................................................................... 4.6% 6.2% 5.3% 6.0%\nConsolidated operating margin.............................................................................. 4.6% 8.0% 6.5% 8.0%\nRevenues\nUnitedHealthcare Employer & Individual - Domestic ................................................ $18,950 $18,646 $38,016 $36,485\nUnitedHealthcare Employer & Individual - Global...................................................... 819 591 1,601 2,123\nUnitedHealthcare Employer & Individual - Total.................................................. 19,769 19,237 39,617 38,608\nUnitedHealthcare Medicare & Retirement.................................................................. 42,623 34,904 84,328 70,390\nUnitedHealthcare Community & State......................................................................... 23,711 19,725 46,775 40,225\nOptum Health................................................................................................................... $25,205 $27,050 $50,514 $53,781\nOptum Insight.................................................................................................................. 4,828 4,543 9,458 9,045\nOptum Rx ......................................................................................................................... 38,459 32,415 73,591 63,250\nOptum eliminations ......................................................................................................... (1,267) (1,129) (2,453) (2,145)\n(a) Earnings from operations for Optum for the three and six months ended June 30, 2025 included $636 and $2,250 for Optum Health; $998 and $1,959 for Optum\nInsight; and $1,441 and $2,759 for Optum Rx, respectively. Earnings from operations for Optum for the three and six months ended June 30, 2024 included $1,919\nand $3,818 for Optum Health; $546 and $1,036 for Optum Insight; and $1,406 and $2,553 for Optum Rx, respectively.\nPage 13 of 16\nUNITEDHEALTH GROUP\nSUPPLEMENTAL FINANCIAL INFORMATION - PEOPLE SERVED AND PERFORMANCE METRICS\n(unaudited)\nUnitedHealthcare Customer Profile\n(in thousands)\nPeople Served June 30, 2025 March 31, 2025 December 31, 2024 June 30, 2024\nCommercial:\nRisk-based...................................................................................... 8,440 8,410 8,845 8,735\nFee-based....................................................................................... 21,530 21,590 20,885 20,835\n Total Commercial......................................................................... 29,970 30,000 29,730 29,570\nMedicare Advantage.......................................................................... 8,350 8,245 7,845 7,770\nMedicaid............................................................................................... 7,490 7,570 7,435 7,410\nMedicare Supplement (Standardized)............................................. 4,305 4,310 4,335 4,335\n Total Community and Senior................................................... 20,145 20,125 19,615 19,515\n Total UnitedHealthcare - Medical............................................ 50,115 50,125 49,345 49,085\nSupplemental Data\nMedicare Part D stand-alone....................................................... 2,800 2,835 3,050 3,065\nSouth American businesses held for sale................................. 1,165 1,160 1,330 1,330\nOptum Performance Metrics\nJune 30, 2025 March 31, 2025 December 31, 2024 June 30, 2024\nOptum Health Consumers Served (in millions) ............................. 98 99 100 104\nOptum Insight Contract Backlog (in billions).................................. $32.1 $32.9 $32.8 $32.6\nOptum Rx Quarterly Adjusted Scripts (in millions)........................ 414 408 422 399\nPage 14 of 16\nUNITEDHEALTH GROUP\nRECONCILIATION OF NON-GAAP FINANCIAL MEASURE\nUse of Non-GAAP Financial Measure\nAdjusted net earnings per share is a non-GAAP financial measure. Non-GAAP financial measures should be considered in addition to, but not as a\nsubstitute for, or superior to, financial measures prepared in accordance with GAAP. Adjustments to adjusted net earnings per share are as follows:\nIntangible Amortization: As amortization fluctuates based on the size and timing of the company\u2019s acquisition activity, management believes this exclusion\nprovides a more useful comparison of the company\u2019s underlying business performance and trends from period to period. While intangible assets contribute\nto the Company\u2019s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings\nper share.\nSouth American Impacts: The loss on the sale of our Brazilian operations completed on February 6, 2024, the loss on our remaining South American\noperations being classified as held for sale and certain other non-recurring matters impacting our South American operations are not representative of the\nCompany\u2019s underlying business performance and therefore management believes the exclusion presents a more useful comparison of the Company\u2019s\nunderlying business performance and trends from period to period.\nDirect Response Costs - Cyberattack: Management believes the exclusion of costs incurred to investigate and remediate the attack, other direct and\nincremental costs incurred as a result of the cyberattack and incremental costs for accommodations to support care providers presents a more useful\ncomparison of the Company\u2019s underlying business performance and trends from period to period.\nPage 15 of 16\nUNITEDHEALTH GROUP\nRECONCILIATION OF NON-GAAP FINANCIAL MEASURE\n(in millions, except per share data; unaudited)\nAdjusted Net Earnings Per Share\nThree Months Ended\nJune 30,\nSix Months Ended\nJune 30,\nProjected Year Ended\nDecember 31,\n2025 2024 2025 2024 2025\nNet earnings attributable to UnitedHealth Group common shareholders ............ $3,406 $4,216 $9,698 $2,807 At least $13,350\nIntangible amortization................................................................................................. 409 417 826 816 ~1,625\nTax effect of intangible amortization........................................................................... (99) (103) (201) (201) ~(400)\nSouth American impacts .............................................................................................. \u2014 1,340 \u2014 8,426 \u2014\nTax effect of South American impacts........................................................................ \u2014 (157) \u2014 (157) \u2014\nDirect response costs - cyberattack........................................................................... \u2014 776 \u2014 1,369 \u2014\nTax effect of direct response costs - cyberattack..................................................... \u2014 (182) \u2014 (323) \u2014\nAdjusted net earnings attributable to UnitedHealth Group common\nshareholders.................................................................................................... $3,716 $6,307 $10,323 $12,737 At least $14,575\nDiluted earnings per share.......................................................................................... $3.74 $4.54 $10.61 $3.02 At least $14.65\nIntangible amortization per share............................................................................... 0.45 0.45 0.90 0.88 ~1.75\nTax effect of intangible amortization per share......................................................... (0.11) (0.11) (0.22) (0.22) ~(0.40)\nSouth American impacts per share............................................................................ \u2014 1.45 \u2014 9.07 \u2014\nTax effect of South American impacts per share...................................................... \u2014 (0.17) \u2014 (0.17) \u2014\nDirect response costs - cyberattack per share......................................................... \u2014 0.84 \u2014 1.47 \u2014\nTax effects of direct response costs - cyberattack per share................................. \u2014 (0.20) \u2014 (0.34) \u2014\nAdjusted diluted earnings per share................................................................... $4.08 $6.80 $11.29 $13.71 At least $16.00\nPage 16 of 16\n\nDATE\nTuesday, July 29, 2025, at 8:45 a.m. ET\n\nCall participants\nChief Executive Officer \u2014 Stephen Hensley\nChief Executive Officer, UnitedHealthcare \u2014 Tim Noel\nChief Executive Officer, Optum \u2014 Patrick Conway\nPresident and Chief Financial Officer \u2014 John Rex\nChief Operating Officer, Optum Health \u2014 Krista Nelson\nChief Executive Officer, Optum Insight \u2014 Divya Surat Devara\nChief Actuary \u2014 Bobby Hunter\nPresident, UnitedHealthcare \u2014 Dan Schumacher\nNeed a quote from a Motley Fool analyst? Email pr@fool.com\n\nRisks\nPervasive medical cost trend pressure\u2014 Tim Noel reported, \"Our current view for 2025 reflects $6.5 billion more in medical costs than we anticipated in our initial outlook,\" with increases observed broadly across Medicare, commercial, and Medicaid lines of business.\nMargin compression in Optum Health\u2014 Patrick Conway stated, \"Optum Health earnings in 2025 are approximately $6.6 billion below our expectations ... with value-based care margins compressed to about 1% in 2025, versus over 3% in 2024 and nearly 5% in 2023.\"\nMedicaid non-dual segment losses in 2026\u2014 Tim Noel said, \"We contemplate negative margins at that time anywhere from negative one to negative one point seven percent for Medicaid in 2026.\"\nContinued membership decline expected in ACA and commercial markets\u2014 Tim Noel noted, \"due to the projected expiration of premium subsidies across the ACA market, our membership should decline significantly,\" with commercial segment declines linked to trend-driven pricing actions.\nTakeaways\nRevenue\u2014 $111.6 billion for Q2 2025, representing a 13% increase over the prior year.\nAdjusted EPS\u2014 Adjusted earnings per share were $4.08, below the same period last year, primarily due to medical cost trends at UnitedHealthcare and Optum Health.\nMedical cost impact\u2014 $6.5 billion in unexpected medical costs for 2025, with $3.6 billion from Medicare, $2.3 billion from commercial (split between ACA and employer), and remaining pressure from Medicaid.\nMedicare Advantage cost trend\u2014 2025 full-year Medicare Advantage medical cost trend now estimated at 7.5%, up from an initial expectation \"just over\" 5%, which was in line with the normalized trend experience in 2024.\nMedicare Supplement trend\u2014 Medicare Supplement trend is expected to be over 11% in 2025, compared to an 8%-9% range in recent years.\nACA exchange losses\u2014 $600 million of unfavorable impacts recognized from ACA exchange business in Q2 2025, including a premium deficiency reserve reflecting higher market-wide morbidity.\nGroup fully insured trend\u2014 Commercial group fully insured medical cost trend is approaching 11% for 2025, about 100 basis points above initial projections.\nBehavioral health in Medicaid\u2014 Medicaid behavioral health cost trend is running at 20% for 2025, contributing to persistent margin challenges.\nOptum Health value-based care margins\u2014 Operating margin in value-based care is approximately 1% for 2025, compared to over 3% in 2024 and nearly 5% in 2023.\nV28 risk model impact\u2014 The V28 industry-wide risk model change is estimated to create an $11 billion headwind for Optum Health over three years, with $7 billion realized to date.\nPlan exits\u2014 Over 600,000 Medicare members will be affected by 2026 product exits, mainly in PPO offerings.\nOptum Health revenue\u2014 Optum Health revenues were $25.2 billion in Q2 2025, down $1.8 billion year-over-year due to contract adjustments and Medicare funding reductions.\nOptum Insight revenue\u2014 Second-quarter 2025 Optum Insight revenues of $4.8 billion increased by $285 million, or 6% year-over-year, but outlook for 2025 was reduced due to slower recovery from last year's cyber event and paused portfolio actions.\nOptumRx growth\u2014 OptumRx revenue grew $6 billion, or 19%, to $38.5 billion in Q2 2025; earnings growth for 2025 was constrained by $510 million in headwinds from portfolio actions, new business investment, and GLP-1 drug costs.\nGuidance update\u2014 Adjusted 2025 earnings outlook is set at a minimum $16 per share; full-year revenues are forecasted to approach $448 billion for 2025.\nMedical care ratio guidance\u2014 Full year 2025 medical care ratio expected at 89.25%, plus or minus 25 basis points, up from an initial midpoint of 86.5%.\nDividend increase\u2014 UnitedHealth increased its dividend by 5% in June 2025.\nCash flow\u2014 Full-year 2025 expected cash flow from operations is about $16 billion, or 1.1 times net income.\nShare count\u2014 Updated 2025 share count projected at 912\u2013914 million, compared with an earlier outlook of 918\u2013923 million shares.\nSummary\nUnitedHealth Group (\nUNH\n+2.53%\n) management disclosed a significant underestimation of 2025 medical cost trends across Medicare, commercial, and Medicaid, resetting expectations for earnings and margins through 2026. The call detailed major strategic and operational changes, including leadership turnover, new technology investments, and remediation efforts to address pricing and risk model shortfalls, notably V28. Segment outlooks highlighted sharp earnings compression in Medicare and value-based care, extensive plan exits, and cost pressures in behavioral health and pharmacy. Management emphasized a multi-year earnings recovery path, capital allocation restraint, and an updated commitment to margin and portfolio discipline.\n\nManagement confirmed Optum Health's long-term margin target is now 6%-8%, with value-based care at 5%, incorporating longer maturation timelines and sustained investment in new cohorts, as stated in the company's long-term outlook.\nPatrick Conway said, \"Optum Health earnings in 2025 are approximately $6.6 billion below our expectations,\" driven by roughly $3.6 billion in value-based care, $2 billion in discontinued portfolio actions, and $1 billion in services and prior period impacts.\nThe planned Amedisys acquisition remains an active capital priority, with company leaders stressing its strategic relevance for in-home and value-based care integration.\nCost reduction and AI adoption -- expected to yield nearly $1 billion in 2026 -- are positioned as enablers for operational execution and longer-term earnings growth, particularly within Optum Health.\nThe full-year medical care ratio for 2025 is projected at 89.25%, up sharply from the previous outlook, reflecting rising service intensity, coding, and lagging rate adjustments, especially in government programs.\nIndustry glossary\nV28 risk model: The 28th version of CMS-HCC risk adjustment used to determine payments to Medicare Advantage plans, introducing substantial funding and scoring changes impacting risk-based care revenue.\nPremium deficiency reserve: A financial reserve established when expected future policy benefits and expenses exceed related premium revenue, as recognized in the ACA exchange business for higher-than-anticipated morbidity.\nGLP-1s: Glucagon-like peptide-1 receptor agonists, a class of specialty drugs impacting pharmacy benefit costs.\nDual Special Needs Plans (D SNPs): Medicare Advantage plans that enroll beneficiaries eligible for both Medicare and Medicaid.\nMedicare Advantage (MA): A type of Medicare health plan offered by private companies that contract with Medicare to provide all Part A and Part B benefits.\nAccountable care arrangements: Healthcare payment and delivery arrangements where providers are financially responsible for patient outcomes and cost efficiency.\nOptum Insight: UnitedHealth\u2019s information and technology segment focused on data, analytics, and managed services for the healthcare ecosystem.\nFull Conference Call Transcript\nStephen Hensley: Thank you. Good morning, and thank you for joining. Today, our prepared remarks will be a little longer than usual, so we will be allowing more time for your questions. As we begin, I want to recognize and thank our employees who have been so dedicated to serving our patients, consumers, and customers during a prolonged challenging period for our business. And I'd like to thank our leadership team, many of whom are new in their roles, for their willingness to join me in looking hard at our businesses, getting a grounded assessment of our action plans, rebaselining our outlook, and moving the pace to advance the performance of each of our businesses.\n\nThis morning, I know you are eager to get into the underlying details of our revised financial outlook. We will do so. But at this moment, I believe it's also important to convey the tone we're setting at this enterprise. More than anything, it is a tone of change and reform born out of recommitment to our mission to help people live healthier lives and help make the health system work better for everyone. It's a mission that requires a commitment to a culture of values, of service, responsibility, integrity, and humility. We pair that mission-driven ambition of reform with a keen sense of the opportunity and the expectation to perform better than we ever have.\n\nAs we continue to assess the state of our businesses, it is very apparent that some require fundamental reorientation. Others require building and nurturing, and others must be reconsidered and redirected to original purpose. We also recognize the need and the opportunity to revisit and address critical processes. Fundamental business practices both internal and market-facing. We are acutely aware we have an enormous responsibility for providing care for millions of people and for protecting the government and private programs we partner in. As such, we have embarked on a real cultural shift in our relationship with regulators and all external stakeholders.\n\nWe intend to be proactively engaged, constructive, and responsive to the concerns of all stakeholders and in our engagement with them. We had the chance to reposition our enterprise as a far more modern, reliable, consumer and provider-friendly enterprise using new technology and approaches, and we're going to pursue that course. Pursuit of these opportunities aligns to and enables our reform and change mandate and allows us to better achieve our mission. We are on this course against a challenging environment, which includes the generational pullback in Medicare funding set in motion in 2023 and playing out through 2026.\n\nUnprecedented medical cost trends measured in both intensity of services used as well as unit prices and more aggressive care provider coding and billing technologies. The prospects for further contraction of the Medicaid and exchange markets, the growing need to invest in the opportunities new technologies offer, and the expectation of all healthcare entities to offer a better experience for consumers, customers, care providers, and employees. And finally, the continuing public controversy over longstanding entire health care sector. Particularly managed care, which bears the critical roles for coverage for care management, and for pricing for the intensity of the cost and services used in the benefit products and programs for the entire health care market.\n\nAs a leading provider of health services, we must help advance a better health system. We are committed to engaging in these pursuits with the sense of purpose and better partnership with all stakeholders. Transparency in our business and reporting practices, and continued integrity in all we do. Beyond the environmental factors that are affecting the entire sector, and more specifically to us, we've made pricing and operational mistakes as well as others. They are getting the needed attention. Our critical processes including risk status, care management, pharmaceuticals, services, and others are being reviewed by independent experts and they will be reviewed every year and reported on. As these processes can be reviewed at any time, by outside stakeholders.\n\nWhile we believe in our oversight and the integrity of these processes wherever they are determined to be at variance with prescribed practice, they'll be promptly remediated. And will continue on this path. All the foregoing is fully addressable. We can steadily restore our performance to levels consistent with our mission and stakeholder expectations. All as we strengthen an institutional culture aligned to that mission and accountable for performance. Over the last sixty days or more, we have made extensive management and operational changes aligned to this agenda of reform and performance. Other such changes to leadership, to our businesses, our culture, our approaches and practices, and to our Board, governance and succession oversight.\n\nAs appropriate, will continue to be made as we proceed through this period. With those thoughts in mind, Tim Knoll and Patrick Conway, Heads of UnitedHealthcare and Optum respectively, will walk through some of the specifics in their businesses. John Rex will discuss financial performance and the elements affecting our outlook, and I'll come back with some closing thoughts and then we'll have ample time for questions and answers.\n\nTim Noel: Thanks, Steve. I'll start by emphasizing that we are approaching our business with greater humility, greater transparency, and a renewed determination to meet your expectations and our standards. The primary driver of the non-healthcare earnings shortfall for 2025 is that our pricing assumptions were well short of actual medical costs. Our current view for 2025 reflects $6.5 billion more in medical costs than we anticipated in our initial outlook. A little over half or $3.6 billion of this is in our broad-based Medicare portfolio. About one third or $2.3 billion is in the commercial business. Split evenly between ACA plans, and our employer business. The remaining trend pressure is related to Medicaid. Most notably due to elevated behavioral trend.\n\nIn addition to trend-driven issues, updated 2025 outlook removes about $1 billion from previously planned portfolio actions that we are no longer pursuing. It also reflects about $850 million of other items including unfavorable prior period items primarily from 2024 and recognition of several one-time settlements. We know these are serious challenges, we are humbled by them and will carry that sense of humility more deeply into our culture. But we also believe we can resolve our current issues and recapture our earnings growth potential. Let me now provide an update on where each business stands starting with Medicare.\n\nWhen we prepared our 2025 Medicare Advantage offerings, back in the first half of 2024, we significantly underestimated the accelerating medical trend and did not modify benefits or plan offerings sufficiently to offset the pressures we are now experiencing. This was compounded by the magnitude of plant exits across the sector and the extent to which we now see care providers placing further service intensity into the health system. The increasingly flexible orientation to which our Medicare networks and plan designs have evolved over recent years left us less able to address these trends in year.\n\nOn trends specifically, the increasing care activity across individual and group Medicare Advantage we saw earlier this year has now affected complex populations and our Medicare supplement business as well. Across Medicare Advantage, physician and outpatient care together represents seventy percent of the pressure year to date. However, inpatient utilization has accelerated through Q2 and we expect will comprise a relatively larger portion of the pressure over the full year. We continue to see utilization increases in ER and observation stays. And consistently see more services being offered and bundled as part of each ER visit and clinical encounter. In short, most encounters are intensifying in services and costing more. The higher trend is broad-based geographically and across our membership.\n\nIncluding our large retained membership base. To put this into context, I had initially assumed Medicare Advantage medical cost trend of just over five percent when configuring our 2025 bids. In line with our normalized trend experience in 2024. We now expect full year 2025 trend to be approximately seven point five percent. Medicare Supplement, which typically is representative of overall care activity levels, and cost trends in Medicare fee for service broadly is up similarly in 2025 compared to historical levels. Expect that trend to be over eleven percent this year versus eight percent to nine percent in recent years. Further confirming the broad-based nature of the care activity and the coding and billing patterns we are seeing.\n\nOn commercial, we are seeing higher than expected medical costs particularly in outpatient care and although to a lesser extent, inpatient care. Orthopedic spending and pharmacy infusions are notable factors here. In the ACA business, the revenue impact resulting from a difference between the morbidity that we price for and what we experienced as the primary cause of our underperformance. One example of the elevated commercial trend is group fully insured. Their trend is approaching eleven percent which is approximately one hundred basis points higher than our initial expectations. Moving to Medicaid. Similar elevated trends are apparent and further affected by increasing and unanticipated acceleration of cost and behavioral health. Where trend is running at twenty percent.\n\nAs well as in pharmacy and home health. We anticipate the existing rate and acuity mismatch will extend well into next year. Beyond these segment-specific factors, there are other broad drivers of higher medical cost. There has been a marked increase in health care cost due in part to increases in service intensity per encounter. For example, in Medicare Advantage, higher frequency of physician rounding, testing, and related services of specialist and in ER settings, are contributing to elevated outpatient spend. In addition to strongly responsive pricing for 2026, which I will speak to in a moment, we are intensifying our remediation actions.\n\nWe have stepped up our audit clinical policy, and payment integrity tools to protect customers and patients from unnecessary costs. These efforts ensure care is delivered in appropriate settings and grounded in safety and quality while also identifying waste and abuse in outlier coding and billing practices. We are shifting to narrower networks and focus particularly in Medicare Advantage. And we have scaled our AI efforts across health plan operations, which improves the patient and provider service experiences while driving cost savings. Lastly, in Medicaid, we continue to actively engage with state partners using both past experience and data-driven insights to show the need for immediate and more regular rate updates.\n\nTaken together, this work is helping restore our operational muscle to and reclaiming executional rigor. Helped by modern tools and driven by a relentless focus on improvement. Turning now to 2026. Our pricing strategy is intensely focused on margin recovery and moving back towards our earnings growth targets. In Medicare, we have historically targeted an operating margin range of three percent to five. Now with the changes from the Inflation Reduction Act, on the Part D program, which resulted in higher revenue but do not impact earnings, the equivalent target margin range is in the two percent to four percent range.\n\nWe are working intensively to remediate Medicare through pricing, product design, and benefit changes that will enable us to be within the lower half of the targeted margin ranges in 2026 and advancing further in 2027. We Medicare Advantage pricing strategy for 2026 compared to our current seven point five percent trend expectation. This accounts for trend acceleration and incorporates factors such as changes in fee schedules and the continuation of higher yield from provider coding and billing practices. Considering the continued cost trends and funding pressures and the need to support margin recovery, we have made significant adjustments to benefits.\n\nAdditionally and unfortunately, given these pressures, we have made the difficult decision to exit plans that currently serve over six hundred thousand members. Primarily in less managed products such as PPO offerings. We have taken similar approaches for Medicare Supplement, Group MA, and standalone Part D pricing for next year. We will be watching the market closely at the 2026 Medicare offerings public. So we can better assess our market positioning and respond quickly. For commercial, because renewals occur over the course of the year, we are able to price for changes more dynamically. Our pricing will anticipate higher trend continuing into 2026 and 2027.\n\nWe expect increased membership decline as well as shifts into both level funded and self-funded product categories because of higher medical cost trends. The individual exchange business, while we are prepared to continue to participate, the majority of the thirty markets we currently serve. We will approach them far more conservatively for 2026. We may need to make the difficult decision to exit select markets if we are unable to achieve the rates necessary for higher market-wide morbidity. Additionally, due to the projected expiration of premium subsidies across the ACA market, our membership should decline significantly. And we are mindful of the potential for adverse selection dynamics as we reprice these offerings for next year.\n\nIn Medicaid, there remains a lag between funding levels and member health risk, and we expect this to continue into 2026. Resulting in additional margin compression in the business, including a loss within the non-dual segment of Medicaid in 2026. Membership losses from early adoption of recent legislation is also factored into our initial views for 2026. Wherever states support responsible funding for Medicaid, we remain committed to serving people through that program view this as integral to our mission. The American health system's longstanding cost problem is accelerating. Are embracing our responsibility continue to drive better health outcomes trying to keep health care affordable for all Americans.\n\nThe operational and pricing strategies I have described reflect our understanding of the challenges we face as a company and a society so that we can set a stable course I'll now turn it over to Patrick Conway, CEO of Optum.\n\nPatrick Conway: Thanks, Tim. Clearly, Optum's performance this year has also not met expectations. Yours or ours. Echoing Tim and Steve, we are approaching this with humility, and the need for deep analysis of key issues and commitment to substantially improved execution. Serving our patients and customers is at the heart of our mission and business and we have the opportunity to truly help make the health system better for everyone. To do that, we need to refocus on our performance discipline, with a bias for action. And transparency for all stakeholders. We have launched our agenda of change at Optum, starting with the evolution of our leadership team. Roger Connor brings tremendous experience in organizational execution, as our chief financial officer.\n\nKrista Nelson is a deeply experienced health care operator now in the new role of chief operating officer. Of Optum Health. Divya Surat Devara, is already energizing reenergizing product development, marketing, and service as the new CEO. Of Optum Insight. And John Mart brings his unmatched pharmacy services experience to bolster the already compelling offerings of OptumRx. These are not the only people in new roles there will be more. We are taking these and many other steps swiftly to enable Optum to recapture its historic momentum. Let me turn now to review of our businesses. Starting with Optum Health, where improved execution is needed most. And we are experiencing the greatest pressures to our business. Our belief remains steadfast.\n\nValue-based care has the potential to transform health care. Yet even as we struggle to align this model with new funding dynamics, it consistently delivers better outcomes. Tim highlighted the challenges of rising health care unit cost, accelerating service volumes, and provider coding intensity. Which further underscores that value-based care remains the most effective method for compensating providers to improve and sustain a patient's health. In contrast to simply increasing the volume and price of services. Research consistently supports this premise. Showing Medicare Advantage patients in fully accountable range are twenty percent less likely to be hospitalized and experience eleven percent fewer ER visits. Compared to those in fee for service. We are early in our value-based care journey.\n\nWe know we have real and self-inflicted executional challenges and we bear the responsibility to get this right. Recognizing that urgent work lies ahead. We have spent a decade assembling a care delivery model today serving nearly twenty million patients across three lines of business. Value-based care, fee for service care delivery, and services. The latter two of which help further enable value-based care. The first category, value-based care, has grown to account for approximately sixty-five percent of Optum Health's revenues and serves five million patients in fully accountable arrangements. I'll provide more details on this in a moment, but first, we'll detail the gap to our original OptumHealth outlook.\n\nOverall, Optum Health earnings in 2025 are approximately $6.6 billion below our expectations. To break this down, approximately $3.6 billion or fifty-five percent is concentrated in our value-based care business with three principal drivers, of roughly equal weight. Number one, the mix of enrollment including more complex and duly eligible members and more new to Optum patients, who are underserved. Two, accelerated medical trend, particularly physician and outpatient in Medicare, and behavioral and Medicaid. And three, underestimation of new members risk status as they came into our care and suboptimal execution. Of the V28 risk model transition. Second category, another $2 billion or thirty percent. Relates to the decision to discontinue previously planned portfolio actions.\n\nAt about $1 billion or fifteen percent, so from a combination of lower service volumes in our services businesses, some nonrecurring prior period impacts, and the slowing of tuck-in acquisitions. For example, on lower service volumes, in 2025, we plan for approximately twenty million fee for service visits in our care delivery clinics, and we are tracking nineteen million visits or five percent below this expectation. Let me dive a bit deeper specifically into factors affecting our value-based care business. First, V28. This industry-wide shift is effectively a price reduction. That we now estimate creating an $11 billion headwind over three years for Optum Health, with $7 billion that'll be realized through 2025.\n\nThat is $2 billion and $1 billion, respectively, more than our initial estimates. While we also overestimated the impact and misexecuted the planned efforts to offset these V28 funding cuts. Second, enrollment mix. Consistent with Q1, 2025, we have an unanticipated number of new to Optum Health patients who are previously underserved. These new patients are largely in markets where numerous plan exits occurred, they include complex patients who require time to be managed effectively by us. This mix impact implies negative margins near double digits for these new patients, which will improve meaningfully in 2026. Lastly, the elevated medical trend we recognize in the second quarter was exacerbated by insufficient pricing within UnitedHealthcare and other payer partners.\n\nDespite these headwinds, Optum's fully accountable value-based care business is delivering an operating margin of about one percent in 2025. This compares to full year operating margins of over three percent in 2024 and nearly five percent in 2023. A large part of the mythic localized management approach, which we are addressing with urgency. We are driving to a consistent and much more concentrated regional operating model with four market leaders. We are evaluating our position in each market. We will shift risk back to the original underwriters until we have the hardened capacity to navigate it under value-based constructs.\n\nAnd Optum will be much more disciplined in taking risk arrangements in product designs and constructs that allow value-based care to have its intended impact. The margin compression reflects significant growth in new membership cohorts. With nearly forty percent of patients served a day having come in since the beginning of 2024. It also reflects the pull through from Medicare Advantage pricing dislocation Tim described and the V28 payment cuts. Regarding patient cohorts, in our value-based care practices, margins improve the longer patients remain. Our most mature value-based care cohorts, those from 2021 and prior, are operating in an estimated eight plus percent margin. 2025. Those in 2022 and 2023 cohorts are operating at a two percent margin.\n\nThe 2024 through 2025 groups are at negative margins. Strong physician engagement appropriate medical diagnosis, and improved consistent quality of care continues to drive year over year improvement in a cohort's financial performance and in their health. But it's taking too long there's too much variability in results among practices. We are actively address those factors. That's the overall picture of what is happening. I'll turn now to remediation. Our plan for improvement has four key elements. First and foremost, we are improving the implementation and consistency of our clinical model, which is anchored in primary care and supported by wraparound services that continue to outperform on quality and cost. Second, we are committed to margin recovery in value-based care.\n\nWe've aligned our 2026 benefits and product portfolio and footprint with our payer partners to address the final year of V28 headwinds. We plan to cease arrangements for about two hundred thousand patients largely and fully accountable of the PPO patients we serve today. We expect to keep narrowing our exposure beyond 2026. We are increasing rates to reflect the higher risk profiles and acuity we are seeing and expect to continue. We believe the combination of these activities will mitigate about half the remaining $4 billion V28 headwind in 2026.\n\nThe remainder of our offset will come from operating cost discipline, and consistent execution of our care programs, which enhance engagement, diagnosis accuracy, and quality outcomes, and reduce overall cost of care. With 2026 being the final year of V28 phase in, you should expect 2026 value-based care margins to remain relatively consistent with the one percent margin we are achieving this year. And then begin to advance again in 2027 and beyond. We are optimizing our portfolio of clinical practices. We are managing our fee for service and fully accountable risk practices to align with performance expectations. Transitioning to partial risk or service arrangements where necessary, and exiting fully accountable products in certain markets.\n\nThird, we are aggressively advancing operational disciplines across our portfolio of businesses. More concentrated operating model I mentioned earlier plays into more standardized approaches which predictable outcomes, and lower operating costs. We will complete the final stages of our technology integration which will enable meaningful advances with emerging technologies, like AI to drive efficiency gains. For 2026, we expect to deliver almost $1 billion in cost reduction. Finally, beyond value-based care, Optum Health also includes fee for service care delivery, including home care, ambulatory surgical care, and medical practices that are not yet fully accountable but support value-based care. These together account for fifteen percent of Optum Health's revenues.\n\nMost of these businesses are performing well and operate at low double-digit margins. However, the primary care multi-specialty medical practices that are not yet fully accountable are running at negative margins. Generating hundreds of millions of losses this year alone. Placing the overall fee for service care delivery business in the mid-single-digit margin range. So we are actually working to improve payment yields and productivity while growing these high-value services and fee for service margins. We are targeting growth for these services, which are projected to deliver strong year-over-year earnings growth. In 2026. The third component of Optum Health services is comprised of businesses including managed behavioral health, military, and veterans, and health financial services.\n\nThese account for about twenty percent of Optum Health revenues and combined have an almost ten percent operating margins. Overall at Optum Health, while we expect continued pressure for the rest of this year, we anticipate meaningful improvement in our operations, and with earnings growth in 2026, albeit with a longer path to recovery in our value-based care business. We now see OptumHealth long-term margins in the six to eight percent range and about five percent for biobased care, specifically. As we see significant growth opportunity. For the decade to come. The overall blended margin will reflect the early year investment losses generated by new cohorts. Optum Health is early in its development and miss execution is a clear setback.\n\nBut the long-term growth potential and expectations remain intact and significant. Moving to OptumInsight. There is a great need and appetite for technology and data products. To help the health system perform more efficiently, and effectively. Yet, OptumInsight has not fully capitalized on this opportunity. That's largely due to an unfocused suite of products lagging innovation, and longer than expected impact from last year's cyberattack. Which unfortunately came at the expense of being able to drill down on business innovation operations, and growth. But as I mentioned earlier, have a talented team in place now and continue to recruit talent to develop the next generation of products. Rooted in AI.\n\nAs it relates specifically to 2025, we are adjusting our outlook downward by $1 billion. About half of this is due to more gradual recovery than initially expected in some of our volume-based businesses. Due to change health care and one-time cyber-related expenses. The other half is due to pausing previously planned portfolio actions so that we can prioritize growth, and innovation across our broader portfolio. At OptumRx, client retention remains high and consistent with past years. We expect revenue growth of $18 billion or thirteen percent, and earnings growth of just over $200 million or nearly four percent. Driven by low margin specialty drugs.\n\nCompared to the strong revenue growth rate, our earnings growth has been constrained by four main factors. The removal of portfolio actions from our plan is roughly a $150 million headwind. Another $50 million is from a couple of ancillary businesses, where we are taking aggressive corrective actions and adjusting plans. The impact of initial launch phase of our private label business, Nuvela, is a roughly $150 million headwind. As it matures, we see Nuveala delivering affordability for our clients and consumers and strong earnings for OptumRx. In addition, GLP-1s, which can benefit appropriate patients, continue to impact earnings representing $160 million headwind our pharmacy services businesses.\n\nAfter three months in this role, I wanna thank the thousands of people serving in Optum. And to let external stakeholders know that the problems are fixable and that Optum will continue to drive long-term growth make the most of our opportunity to serve people. I'll turn it over to our president and chief financial officer, John Rex.\n\nJohn Rex: Thanks, Patrick. I'll first walk through second quarter results, then provide some color around the underlying assumptions within our reestablished 2025 outlook. Starting with the second quarter, UnitedHealth Group reported revenues of nearly $112 billion a thirteen percent increase over the prior year. Which reflected growth across UnitedHealthcare and Optum. Adjusted earnings per share of $4.08 was below the same period last year. This was due primarily to the pricing and medical cost trend factors at UnitedHealth Care and OptumHealth. Included is about $1.2 billion in discrete items. So a little over half reflects the recognition of unfavorable impacts to our ACA exchange offerings, which I will describe later in more detail.\n\nThe remainder is the settlement of several outstanding items which have been in dispute or for which collection has recently become questionable. Most of these items arise from prior years. The full year 2025 outlook we've offered today accommodates $1 billion in additional potential such items that we may seek to resolve in year. Now on to business overviews. At UnitedHealthcare, second quarter revenues grew by over $12 billion to $86.1 billion while operating earnings declined by $1.9 billion to $2.1 billion primarily due to the medical trend factors Tim discussed. Within our Medicare businesses, year to date Medicare Advantage growth is six hundred and fifty thousand people including those who are duly eligible for Medicaid and Medicare.\n\nAs noted, the second quarter results reflect just over $600 million of unfavorable impacts from our ACA exchange business. Which includes acceleration of anticipated second half losses with the establishment of a premium deficiency reserve. This is due to the higher patient morbidity that is pervasive across the entire exchange market. Given competitive market dynamics, we have less member growth within our commercial offerings than initially anticipated. ACA exchange drives about one third of our reduced commercial risk member growth outlook for 2025, with group insured comprising much of the rest.\n\nAs outlined earlier, our Medicaid Our state partners remain highly engaged in ongoing rate conversations and we are closely attuned to the federal funding changes and the continued pace of medical cost trends. Moving to Optum, Optum Health revenues were $25.2 billion in the second quarter, a decline of $1.8 billion from last year. This was driven by the previously noted contract adjustments and the effects of the Medicare funding reductions. Austin Health now expects to add three hundred thousand new value-based care patients this year. Compared to the initial six hundred and fifty thousand outlook. As it seeks to focus on improving operating performance. As noted, we've updated our long-term target margin objective for OptumHealth.\n\nTo the six percent to eight percent range. OptumInsight had revenues of $4.8 billion an increase of $285 million or six percent year over year. We continue to progress on customer recovery following last year's cyber event. Albeit pacing more slowly than expected, and this is a component of the reduced full year outlook. The contract revenue backlog at the end of the second quarter was $32.1 billion. OptumRx second quarter revenues grew $6 billion or nineteen percent over last year to $38.5 billion. Driven by new customer adds, as well as continued contribution from specialty products. Total adjusted scripts were four hundred and fourteen million compared to three hundred and ninety-nine million in the year-ago quarter.\n\nMoving on to 2025 guidance. Our adjusted earnings outlook is at least $16 per share. Revenues will approach $448 billion growth of eleven percent over 2024. We now expect a full year medical care ratio of 89.25% plus or minus twenty-five basis points. This compares to the initial 86.5% midpoint we offered at the end of last year. With the increase driven by the factors discussed. Within this seasonal pacing compared to historical measures is impacted somewhat by the Part D coverage gap modifications due to the inflation reduction act. With first half results, at the midpoint, that places the second half at just under 91.5%.\n\nWith the fourth quarter expected to be the highest, and at this distance, a relatively proportionate distribution on either side. The full year outlook contemplates a total of $1.6 billion of potential settlement items, an incremental $1 billion over the $600 million recognized in the second quarter. Our tax rate for the year is now estimated at about 18.5%. Affected by our revised earnings outlook as expected benefits remain steady while earnings declined. The lower tax expense in the second quarter reflects the year-to-date recognition of the updated full year effective tax rate. We expect the second half rate to be just over twenty percent.\n\nFull year 2025 cash flows from operations are expected to be about $16 billion or one point one times net income. In June, we increased our dividend by five percent and we will strike a balance as to how we use capital over the near term. Being thoughtful about maintaining a strong balance sheet credit rating, and mindful of long-standing commitments. Including the pending Amedisys transaction. Our updated share count of nine hundred and twelve to nine fourteen million dollars compares to the original outlook of nine zero eight eighteen to nine hundred and twenty-three million dollars and considers only share repurchase completed earlier this year.\n\nWe will continue to balance and assess our capital priorities as we progress to returning to the performance levels we know we can achieve. With that, I will hand it back over to Steve before we head into Q and A.\n\nStephen Hensley: Thanks, John. This is a challenging year for our enterprise. But I feel strongly we can overcome these challenges as we've done before. I can see the depth of the commitment of our team, we are regaining the intensity, the precision, and the executional disciplines required to perform consistently and reliably. Our customers and our shareholders deserve it and the health system expects us to function at our full potential. As we look towards 2026 and beyond, we expect the efforts we discuss throughout today is called steadily improve our performance. It begins with respecting pricing basics, advancing our foresight acumen, and just better, more intense, more decisive overall management.\n\nWe will be driving better business practices, better consumer and provider experience, and accelerating investments in areas in key areas to both strengthen our foundations and modernize our businesses anchored in practical innovations and scaled AI applications. We are continuing to evaluate the investments we need to make in the near term to meet our long-term growth potential while acknowledging the challenging environment in the year ahead. As I mentioned at our shareholder meeting in June, we're rebuilding the trust to both change and through increased transparency. That includes work to ensure a wide range of stakeholders have confidence in the integrity of our company and our business practices.\n\nThis work is moving forward in our assessment of key policies, practices and associated processes by the end of the third quarter and our first performance measures report in the fourth quarter. We have retained independent experts to oversee an assist in these reviews, including the analysis group, and FTI Consulting. We will use this to continually strengthen advance our strong compliance environment. Looking to 2026 at this distance, I would expect solid but moderate earnings growth. As we look further ahead we see our earnings growth outlook strengthening quickly in 2027 and pacing steadily upward over the succeeding years. Now let's open it up for questions. Operator, please.\n\nOperator: The floor is now open for questions. At this time, if you have a question or comment, please press star one on your touch tone phone. You may remove yourself from the queue by pressing star two on your touch tone phone. We ask you to limit yourself to one question. If you ask multiple questions, we will only be answering the first question that we can respond to everyone in the queue this morning. Our first question comes from AJ Rice with UBS.\n\nAJ Rice: Hi, everybody. Maybe just to drill down a little bit on Optum Health, if I could. You're talking about some rate increases or how you're pricing for a much higher trend in MA on the insurance side. I would assume that has some trickle-down benefit to Optum Health or when you're talking about having margin consistent with this year, next year on the position piece. Is that does that not contemplate some benefit from that repricing? And maybe as well talk about your discussions with the outside plans that OptumHealth contracts. I mean, are you seeing them make same similar steps toward pricing for a more reasonable margin next year that you're trying to do at UHC?\n\nIt certainly does, AJ. Patrick, do you wanna comment?\n\nPatrick Conway: Yeah. Thanks, AJ, for the question. Let me take the sort of pieces in parts. So yes, in terms of the pricing across payers, UnitedHealthcare and other payers, as they adjust price that flows into our capitation rates. That is a tailwind. Where versus the headwind we saw this year. We're also working with our payer partners on benefit reductions, which we talked about. So significant benefit reductions across payer partners and a much tighter, transparent, bidirectional dialogue in this year, which I think sets us up better for next year. Those combinations, we think, mitigates fifty percent of the headwind of V28 as you heard, we sized at $4 billion for next year.\n\nThe other two components that will mitigate the other fifty percent one, operating cost reductions where we continue to hone our model using AI and other tools generating operating cost reductions. And then next, you know, deep engagement with the patient cohorts we see. So as you heard, as we mature and remain stable in those we believe we can maintain those margins at the one percent level. The approach this year with our payers has been tight. Close, and I think will bear benefits going into 2026.\n\nStephen Hensley: Thank you, Pat. Next question.\n\nOperator: Our next question comes from Justin Lake with Wolfe Research.\n\nJustin Lake: Thanks. Good morning. Appreciate all the detail. Wanted to focus on the run rate out of 2025 into 2026. So it looks like you're about five dollars of earnings for the second half. Back about a dollar for the discrete items that John mentioned. You're about six bucks given typical seasonality. Maybe that's, like, thirteen dollars of run rate earnings. So I wanted to see if that's reasonable math first. And then what are the moving parts that drive EPS growth specifically? Maybe you could talk to where your MA margins are this year versus where you expect them to be next year. Thanks.\n\nJohn Rex: Hey, Justin. Good morning. It's John. Just a few comments on that. So, yes, your overall kind of assessment of second half is correct. A few things I'd point to and then I think that's Tim and Bobby to comment a little bit also on as we talk about Medicare Advantage. Margins and where that goes. I mean, the key elements here so, yes, we are kind of looking at it, getting some things behind us in terms of the actions we're taking, we anticipate taking in the second half. And as you know, really, quite well, eighty percent of our premium revenues reprice on January one.\n\nSo very significant impact in terms of that as you move into that next year in terms of the impact that creates in terms of off the run rate that you see going into the second half. And I've asked Bobby to maybe comment a little bit specifically on your piece on Medicare Advantage.\n\nBobby Hunter: Yeah. Thanks, Justin, for the question. Thanks, John. So Justin, when you think about, you know, 2026 or 2025, where we're likely to kind of pencil out for the balance of the year here is more in the low end of the new normal range that Tim outlined in his prepared remarks. So I think kind of the two to two and a half percent range, and I'm talking about kinda all broad-based. You would see Medicare in that bucket.\n\nAnd then given the actions that we're taking for 2026, so the meaningful benefit cuts, the plan reductions, the trend that we're pricing towards, we do believe that'll allow us to overcome some of the headwinds, again, tied to, you know, V20 funding cuts and that embedded trend. And expand those margins to a range of two and a half to three percent. Think about us then getting to kind of the midpoint of that range by 2027 and advancing from there. Thanks for the question.\n\nJohn Rex: So, Justin, yeah, really kind of the math that you're looking at here. So continued trend accelerations that we look at through the end of the year while our revenues are staying the same. And then we get to Jan one where the major vast majority of our premium revenues reprice.\n\nStephen Hensley: Thank you. Next question, please.\n\nOperator: Our next question comes from Josh Raskin with Nephron Research.\n\nJosh Raskin: Thanks. Good morning. I appreciate some of the commentary you've made on 2026 and 2027 even. Do you have an updated view on your long-term EPS growth rate that, you know, was formerly cited as thirteen to sixteen percent at the enterprise level. And then I heard the target margin's obviously updated for Optum Health. But do you have updated target margins for maybe UHC in its entirety as well as the other two segments within Optum?\n\nStephen Hensley: Yeah. Thanks, Josh, for the question. You know, as you can appreciate, as we're just coming back on stream, in the near term, our growth rates do not reflect, I think, the potential of this enterprise. So from it's somewhat academic. But I expect we will pace back steadily to low double-digit ranges and continue to advance from there. And I think importantly, the framework for our long-term growth outlook remains very much intact.\n\nFrom within well-run businesses, reasonable year-over-year organic growth, the compounding effect of deliberate productivity gains, the compounding effect of capital applied in the form of share buyback as we return value and capital to shareholders and the compounding effect of capital used in evolving the business model toward a more expansive view of the healthcare markets. That is less fragmented and more integrated to better serve consumers and the overall system. And the components of that should allow us to continue to grow at strong levels we've experienced in the past. And that's our outlook on it. And, Josh, just maybe a little bit on margin. Maybe Tim has a comment.\n\nHe made some comments on Medicare particular with the IRA changes. And, Tim, maybe if you just could reflect on those.\n\nTim Noel: Good morning, Jeff. Thank you. So, you know, we talked about the reframing of the fraud-based Medicare Advantage targeted margin range really kind of really not all that different, just the mechanical implications of more revenue coming through the IRA without, necessarily any incremental earnings. Then as Bobby just talked about, you know, we see that pacing to the closer to the midpoint in 2026. And getting there in 2027. On the commercial business, 2026 will be a year where we'll not get all the way into our target margin range seven to nine percent, but certainly see a path to get there thereafter. So really no change bottom line. To the targeted margin range across UHC.\n\nJohn Rex: John, any more? I think just maybe Tim's comment that he made on call in terms of how he thinks about Medicare Advantage with the addition of those IRA dollars and such. Doesn't change really the productivity of the business. It's just that piece of the revenue impacts the margin count calculation that came in piece of revenue that came in without really any earnings attached. To it to when it came in. So similar profile. And in general, I don't think we were actually ever seeing the full portfolio of Opta perform to its full potential.\n\nSo I think there's that should be strongly additive as well as the emergence of the Optum Insight businesses strong margins that are coming off the platform of more technology-enabled service. So those elements play in, but it is so early in our restart that to me, the discussion of a long-term growth rate seems somewhat academic other than the framework. For our historical outlook remains fully intact. Next question.\n\nOperator: The next question comes from Kevin Fischbeck with Bank of America.\n\nKevin Fischbeck: K. Great. Thanks. You know, in your commentary around the guidance reduction, you mentioned across a number of businesses that you had portfolio actions that you're delaying. Can you talk a little bit about what exactly those types of actions were across the businesses? And are those potential savings still something that you think you're gonna execute on, or are those not the right way to think about as, you know, adding those up and then coming up with earnings power number at some point over the next couple of years. Thanks.\n\nStephen Hensley: Clarify the question.\n\nKevin Fischbeck: Yep.\n\nStephen Hensley: I'm not sure I understand the portfolio actually.\n\nKevin Fischbeck: Yeah. You mentioned a number of things, like, when you're trying to bridge, we between, like, you know, the Medicare Advantage. Results this year versus you know, what you've assumed would happen. You put I think you put some buckets in there saying that you were gonna do some things, and then you decided to put them on pause. Is that not the right way to think about it?\n\nStephen Hensley: These are on transactions. Yeah. So I that's a good question because I do think that needs to be clarified. The company pursued kind of a re-evaluation of the portfolio of all of businesses. Last year and we're taking actions to position some of the businesses and divested some that I think is evident in our results. And as I came in and looked at that, my orientation is to pursue more of the performance of the business portfolio that we have, make those businesses perform to their full potential. I think the that portfolio needs to be considered in light of you know, what I think the real performance potential is.\n\nAnd so we stopped that entire activity and some of that was considered in the outlook in the current year, and that has been withdrawn completely. And we are focused on the performance of the businesses that we have, and we'll pick up portfolio assessment somewhere down the road. But right now, our focus is on the portfolio that we have, and we have removed any of that from our outlook.\n\nKevin Fischbeck: Okay. Thank you.\n\nStephen Hensley: Kevin, does that answer your question?\n\nKevin Fischbeck: Actually, what yes. Maybe just to clarify. So are these businesses that you thought you were gonna be losing money and you're now going to keep them focusing on the earnings power going forward? Or was there something around gains on sales or things like that you were gonna recognize from divesting things that you're not gonna include in the package.\n\nStephen Hensley: Oh, I think that's a much more complex issue, Kevin. I think the motivations for thought were better in the hands of others. Others we're let's want to be, let's say, not core, but we're really not to pay the net right now. All solid businesses and we'll continue to run them and optimize their performance and then consider their long-term standing in our portfolio. Next question, please.\n\nOperator: Our next question comes from Lance Wilkes with Bernstein.\n\nLance Wilkes: Great. Can you talk a little bit about the management process and strategic review process that you've undertaken with the company and where you are to date with that, maybe providing some insight into what the management process was previously and the changes you've made to it. And then from a strategic review process, would you say you're completed with any sort of strategic review or are there any sort of timeline associated with future strategic review? Thanks.\n\nStephen Hensley: Well, I'm not sure I know what you mean by strategic review, but just to kind of thematically address this probably just seventy plus days in. Kind of returning to what I would call very basic fundamental discipline. So much greater intensity around depth of review of the businesses, underlying financial levers, etcetera. Core, the economic levers in the businesses. You know, basically, just a much more intense sit man monthly management review of business performance, not just on financials, but on operating metrics, on relationships with the external stakeholders, on future potential, on the progress made on remediation efforts and programs offsetting some of the headwinds that we have discussed this morning, like V28 and so forth.\n\nSo just a really comprehensive business by business review. And assessment of the prospects of the businesses, I'd say, relatively in the near term. Much more broader engagement of the management team and engaging our resources across the enterprise to take a just a very fresh objective look to things that let's say, faster decision making, changes in people. There have been, I think, as Patrick described, pretty far-reaching changes across the entire in motion across our other businesses and across corporate. So I'm just basically rambling to give you a sense that is much more intensive. And leadership team has really engaged exceptionally well like that.\n\nAnd I just think there is a new tone and a new expectation setting in. And then we are going to continue to drill down on these businesses and get much more granular, particularly as we get in and complete the 2026 planning process. So I think that gives you a feel for it.\n\nLance Wilkes: Great. Thanks.\n\nOperator: Our next question comes from Lisa Gill with JPMorgan.\n\nLisa Gill: Thanks very much. Good morning. Steve, when you talked about 2026, you talked about the steady improvement, but you also said you need to evaluate investments. How should I think about that for 2026? Are there incremental costs that you need to bring online? You know, other investments that you need to make in the business as we think about 2026. And if we have incremental investments in 2026, how do we think about the returns on those investments in the timeline?\n\nStephen Hensley: Mhmm. So I you know, coming into kinda returning to this environment, you obviously looked at particularly with the results at the cost structures, the organizational approaches that have been taken and so forth, and you know, I think there are meaningful cost opportunities within the enterprise, but I and we are pursuing them with urgency. But I also believe that we should be balanced that there are areas that we have underinvested, and they include areas of OptumInsight where Patrick talked about the performance challenges there. Optum Insight I think, can be a remarkable business, but we need to pay more attention to it, make sure it has stable and deep leadership.\n\nAnd we need to make the investments in the in updating the product offerings, which are largely a portfolio of point-to-point solutions. And with the technology capacities we have and the expertise we have, make them much more compelling end-to-end kind of impacts. And that would be just one example. I think our AI agenda, Sandeep, has gotten real traction on that agenda, and I intend to accelerate it. To really infuse this entire enterprise with an AI-first orientation. And also use that as a means to develop the capabilities to again, revitalize products really across the enterprise.\n\nI'd also tell you that, again, in what I'll I'll view as Optum Insight, Divya who's leading that business, the fintech agenda for that could also be compelling and has also been underinvested in. We haven't had excellent and distinctive platform there. And we need to push forward on that. So I think there are so many areas of opportunity that really are near term for us. Do I think they will translate? I think they'll translate into good contributions for 2026, but I think not only we need a little money, we need a little bit of time. And so I do think 2027, 2028 is really where you're going to see acceleration in those for sure in 2027.\n\nSo does that give you a feel for those kinds of things? And I don't know, Patrick or Divya, if you have other commentary.\n\nPatrick Conway: So just briefly building what Steve said and then Divya, feel free to add on. Look, I think Optum Insight and Optum Financial and the AI agenda are a large area of opportunity as we interact with clients and customers. We hear that from payers, providers, others. They want our support in those areas. So I think it's both external and internal. Internal on cost savings external on growth and innovation as Steve alluded to. And Divya, turn over to you if you wanna add more.\n\nDivya Surat Devara: Yeah. Lisa, coming into this business and just giving it a fresh look, there's a lot to be optimistic about. Both of these businesses, Optum Insight and Optum Financial. There's some structural tailwinds when you think about it. Firstly, as Steve said, payers and providers are looking for tech-forward solutions to help solve their problems and the headwinds that they face. And coming in, I'm finding that we have deep customer relationships and domain knowledge that'll help us do that. On top of that, combining Optum Insight and Optum Financial, we're able to create unified solutions that are gonna offer the market a lot more financial flexibility, and that's something that the market really needs.\n\nSo what we're doing is taking all these trends and work coming up with a product portfolio that's AI-based. And we're launching we've already launched this year an AI-powered RCM solution. Later this year, we'll be launching an AI-powered real-time coordination of benefits. So think of this as early innings in our product journey. And we're gonna have more launches coming out in the coming quarters and years which makes me very optimistic about the future of the business. As Steve said, is not an area we've focused in the past, but we have the right strategy. We have the right investments. And we have the right team to go execute. Thank you.\n\nStephen Hensley: And I'll just make two other comments and one pretty basic, and that is you come in and you take a look and you see cost opportunities for sure starting at corporate and the and the corporate versions of the business units. And you basically are sitting back saying, we're gonna we're gonna pull those back, and we're going to make the investments in the businesses that we think can produce remarkable performance for us going forward. High margin businesses, etcetera.\n\nAnd that plays into the long-term growth view, and that is if we execute on those, which have always been in our strategic sites, the contributions of those can be distinctive and plays into you know, a very positive long-term growth outlook.\n\nOperator: Our next question comes from Steven Baxter with Wells Fargo.\n\nSteven Baxter: Yeah. Hi. Thanks. I think you suggested the long-term target margin for value-based care is now five percent. Think this is also, you know, what you suggested the business earned just recently is 2023 before the onset of the V28. So it just might be helpful to better understand. I guess, what were the old value-based care target margins to compare the five percent to? I heard you, you know, loud and clear talk about, you know, expected stability in 2026. You better help us understand the margin drivers, you know, beyond 2026? With the exception maybe of the NMA repricing, which we already understand to get back to that five percent? Thank you.\n\nStephen Hensley: Yeah. So maybe we'll start with Patrick, and then if John wants to comment about the kind of the change in perspective on margins there. Patrick?\n\nPatrick Conway: Yeah. So thanks, Steven, for the question. So you did hear correctly, Optum Health margin all in, six to eight percent. Value-based care, as we sit today, you know, estimating around that five percent level. Really, the issue is the significant revenue hit to the system with V28 and what that meant and adjusting the curve adjusting the impact I'd point you back to the cohorts that we called out. I think this is critical. In years one and two, which is about forty percent of our membership as we stand today in 2025, negative margins. Year's three to four cohorts. Two percent margins. Year five plus, eight plus percent margins.\n\nIf you look at the progression as we focus on you know, taking risk in markets that we're confident in our ability to perform and in products, primarily HMO. Confident in our ability to perform, focused on employed and contracted positions, you should see those cohort shifts. So years one to two will be more in the range of twenty-five to thirty percent of the portfolio. Years five plus, more forty plus percent. That gets you to that five range in terms of margins. And then as you heard on the services businesses, we'll continue to grow those. And I'd call out in care delivery fee per service. We have an opportunity for both growth and margin improvement.\n\nHome health, low double digits, surgical centers in the range of twenty percent, in care deliveries in our clinics, we've got opportunities, and especially in some regions, improve and improve the performance of the care delivery service bucket.\n\nJohn Rex: And, Steven, it's considering the change in the Optum Health margin target, most of that is driven by really the value-based care perspective. And what's going on there is really we are we being a little more circumspect about how long it takes to get these practices into the zone that we needed them to be in. So the appropriate amount of time to get them performing as they should perform that's a component there. The conversion for those that are still mostly fee for service and getting those into a position of where they can actually also start becoming fully accountable practices. Important elements in that.\n\nAnd then this perspective that at five million patients served today, that should be the addressable market is much larger than that. And that we will continue be continuing to do this for a decade as past made in his has stated in his prepared comments and the investments of that take. So little more circumspect about the investments that we need to put in to bring these to bring these into full fully print full production. Patrick noted that some of the longest standing vintages of our or cohorts of members are performing at eight percent plus margins.\n\nBut it just it's we're giving ourselves more time to get there and also giving ourselves time more investment room, maybe echoing a little on Steve said in terms of the investments we need to make into getting them fully ready and to be performing and that we'll be making these investments for the next decade as we grow this business. Or more. So six to eight becomes a much more rational and better guidance outlook. So good question. Thank you for asking it. Next, please.\n\nOperator: Our next question comes from Sarah James with Cantor Fitzgerald.\n\nSarah James: Thank you. Can you talk about any changes you've made in your management review process of underwriting assumptions and conservatism? And the independent party review that you talked about, does that involve any of your underwriting process? Thank you.\n\nStephen Hensley: So yes. First of all, I'll have maybe Tim comment about kind of underwriting perspectives. As well and maybe then Dan Schumacher because kind of from an enterprise point of view, we are looking at you know, let's say, strengthening underwriting and making sure that we are taking it a total enterprise view from a underwriting point of view. So, Tim, you wanna start?\n\nTim Noel: Yeah. Thanks for the question, Sarah. So with respect to know, underwriting and the processes associated with that, know, we still feel like, we have know, very strong people processes in place, to submit product filings, to analyze and assess our business. And I think that's, you know, one of the reasons why we have a very clear view on what's happened in 2025. If there's one change that change would be that I think we're a little bit more respectful of the environment that we're in and the dynamic nature of it. And we're contemplating that as we think about our pricing in all of our businesses, commercial, Medicare.\n\nAnd then we're gonna use those data and analytics on the Medicaid side to approach our partners, our state partners with data-driven insights. As we talk about how to configure rates appropriately moving forward so that revenue mat matches the new acuity of these populations. But, you know, no fundamental change in the processes and people. We're very strong there. And these analytics will frankly drive the approach that we're seeing, which I think is appropriate and respect of what's going on broadly in the health care industry. Dan?\n\nDan Schumacher: Good morning, Jared. This is Dan. So at the enterprise level, we are working to strengthen our forecasting process. We've implemented an, you know, internal audit review that examines our guidance and the work that we put into that. But, also, we're strengthening our actuarial resource base. And to Tim's point, we'll be looking at you know, the underlying trend builds across the company and across membership cohorts as well as the revenue composition. Obviously, revenue's complex when you think about the interactions between you know, risk model changes and so forth. So we'll be doing that as well.\n\nAnd, likewise, building out and strengthening our analytics taking advantage of new approaches, working with Sandeep on the AI front, and pulling in signals earlier and being able to adapt to those more quickly and then propagate them rapidly across the enterprise. So those are some of the things that we have underway.\n\nStephen Hensley: Yeah. And I think we already use third-party experts in our processes. So that would not be anything new. And I think we probably use as much or have most of the resource in the marketplace along those lines and have for years. But at the end of the day, as those processes come to closure, judgments are made and judgments are made about market reads and how markets are predicted to perform. And I think those judgments are some of the areas that are kind of sensitive in terms of outlook right now. And the oversight of those judgments and the conservativeness of them is also something we are taking into place and broadening those decisions across the enterprise.\n\nSo a good question, but it is definitely among the processes that are under review across the enterprise.\n\nOperator: Our next question comes from Andrew Mok with Barclays.\n\nAndrew Mok: Hi. Good morning. Wanted to follow-up on Medicare margins. If we think about the three patient populations in Medicare Advantage, retail, group, and special needs. Can you compare the relative margin profiles and different paths of margin recovery for each including which population is most addressable near term. Thanks.\n\nBobby Hunter: Please. Yeah. Hey. Good morning, Andrew. Bobby here. So yep. When you again, overall margins for 2025, think about two to two and a half percent 2026 expanding to twenty-two point five to three. Yeah. We talked about early in the year some of the pressures that we were seeing in the group business in particular with the trend pressure kinda overweight in that area, you know, I would say that phenomenon has continued. We continue to see certainly pressure the medical side across all populations, but that one in particular has been elevated know, group, as you kinda know, does have the opportunity to reprice each year, not dissimilar from, you know, individual MA.\n\nAnd we are pursuing those discussions with our group customers. So think about the majority of those being able to be repriced on a given year, and that is absolutely kind of the path that we're moving down. On the retail and snip portions, you know, I would say both performing, you know, generally in line. Obviously, more of our growth this year is coming in both the D SNP and C SNP space. We saw that in the AP. We've continued to see that as the years progress. On balance. You know, that growth is accretive to the enterprise. Those are areas that we're going to continue to focus.\n\nI think we have the broad care management tools you know, really that kind of best equip us in partnership with some of our value-based care providers like Optum to really effectively manage that population. That's gonna be an area you continue to see us lean into, heavily and bring the full capabilities and assets of the enterprise. And on the retail side, you know, we talked about, obviously, the different approach we're taking to trend for 2026. And different approach that we're taking to the products, the benefits, exiting a significant number of plans and obviously impacting it Tim noted, about six hundred thousand plus members that is predominantly in the PPO space.\n\nAnd think about roughly a third of those is kind of full market or submarket exits. So, you know, meaningful adjustments coming both on the other individual side and the group side to help advance that margin progression for 2026.\n\nStephen Hensley: Thank you. Next question, please.\n\nOperator: Our next question comes from Ann Hynes with Mizuho Securities.\n\nAnn Hynes: Great. Thank you. I don't know if you addressed it on the call, but can you remind us what your target margin is for Medicaid and what you would expect it to be in 2026. And then just a follow-up, John, you had talked about eighty percent of the premium next year. Will increase because the pricing cycle should improve in 2026 for the industry. Can you give us a compounded increase that you expect? That'd be great. Thank you.\n\nMichael: Thank you for the question. For 2025, we expect breakeven performance for a non-dual core Medicaid business under community and state. Our 2025 Medicaid earnings outlook is down modest persistent high medical trend stemming from care usage levels that are really higher than we realized in the final stages of redetermination. And also increased service intensity per encounter as identified within our claims data. We do expect some degradation with our cost benefits ratio driven by the twelve eighteen month lag that we see in our core Medicaid rating cycle process. And as we think about 2026, we contemplate negative margins at that time anywhere from negative one to negative one point seven percent. Thank you for the question.\n\nJohn Rex: And this is John following up on the rest of your question here. A few comments. So I'm gonna ask some of the UnitedHealthcare people to contribute to this here. But as Bobby and Tim have explained, a lot of what happens in Medicare Advantage, you know, is the benefit cost trend assumptions are building in and they talked to looking towards the about a ten percent trend for 2026 with the actual rate of premium increase determined by what CMS has come out with. But let's get a little deeper into that and talk about specific components, maybe even get into commercial and some of the things that we're doing in there.\n\nTim, I'll lead it with you and just go ahead.\n\nTim Noel: Yeah. So answering the question around, you know, our long-term margins in the Medicaid business itself, you know, excluding the dual special needs plans in Canadian state. The rated margin, that we attempt to attain with the states is around a two percent margin. Historically, we've talked about blending to a three to five percent margin within the community and state segment. Given the adjustments we've talked about around Medicare Advantage broadly, moving from three to five to two to four because of the impact of the inflation reduction act, we'd expect that to be, you know, mirrored in the community and state growth targets.\n\nSo, you know, two to four still in community and state or adjusted to in community state and Medicaid would be kind of a two percent targeted margin.\n\nJohn Rex: And Anne, in terms of your you know, the point you were making about kind of premium increases one would expect in 2026 as you go into that overall on the eighty percent of premiums renewal. So Bobby and Tim, shaping up what happens in kind of those businesses, those government program businesses and the premiums coming from those customers and then what they're doing in the benefit design underneath there. And then maybe it'd be helpful if Dan Keter comment a little bit on some of the pricing expectations in commercial markets and what he's seeing there because that's another important part of what's driving that premium increase in that marketplace.\n\nDan Schumacher: Yeah, John. Sure can. 2025, as noted in Tim's remarks, trend in the commercial group business has materialized a hundred basis points above our expectation, which has created some trend pressure I'm sorry. Trend and margin pressure. So we are well below our margin range for the commercial business of seven to nine percent this year. As we look to 2026, we're pricing for margin recovery in both the exchange business and the group business. This will lift our margins to be closer to but modestly short of our target margin range of seven percent to nine percent. We expect to recover into that range for 2027, as been previously noted.\n\nTo provide that margin expansion and recovery in 2026 with our trend outlook to be above eleven percent. We are pricing with that fully in mind.\n\nDan Schumacher: Hey, Anne. This is Dan. Just to round it out in terms of the premium increases, you know, so what Dan just described in the commercial business, you should think in terms of, you know, double digit on that one. On the Medicaid side, we're operating at about a combined six percent premium increasing 2025 and would expect that to be comparable as we move into 2026. And then obviously on the Medicare side, as John mentioned, that would track with what the CMS adjustments were. K. Next question, please.\n\nOperator: Our next question comes from Matthew Gillmor with KeyBanc.\n\nMatthew Gillmor: Hey. Thanks for the question. So the settlements you called out, they're part of the discrete items. Can you get some detail on nature of those settlements? Are those mostly tied to value-based care contracts and Optum Health? And if that's the case, can we think about the Optum Health network 2025 as being burdened by about one and a half billion of those settlements that hopefully don't repeat next year?\n\nJohn Rex: Matt, John Rep here. So I wouldn't call it necessarily mostly tied to that. It is across businesses. Think of these things as ranging from elements like you've described, but I would put it more in the context potentially in some areas that company receivables we have from other companies that we from for which we have are we started questioning whether or not they're collectible. And so as it moved into that zone, we've taken we've taken some provisioning for those. Other areas where just disputed items. And in this business, you know, there can be disputed items that persist for some period of time.\n\nAnd think as we were taking a fresh look and we are coming to come out with our outlook for the year, making sure that we had contemplated all those so we could get some of those settlement items out of the way. So think about it as both. In the zone of receivables where we question the collectability, maybe a dispute with a customer over some over amounts over amounts and these dating back a year or more. Sometimes in terms of where they might be. Sometimes with providers, also, in terms of areas we were, that we were looking at.\n\nSo it's really a collection of items that we that we came at, but I wouldn't call it predominantly. I mean, there's there's certainly a there's certainly a good amount of that sitting in OptumHealth too. But I wouldn't call it predominant in terms of those amounts. So that gives you a little flavor for some of the items that we're trying to...\n\nStephen Hemsley: Generally split them so they get some idea of what they're overcoming.\n\nJohn Rex: Yeah. I would say kind of within OptumHealth, think of that kind of as in the zone of, like, take the full amount of probably about half a billion or so sitting within OptumHealth. We'd call it we called on a call Tim called on a call eight hundred and fifty million within UnitedHealthcare and then a couple hundred million in Optum Insight. And little under a hundred million in that zone in OptumRx and then a smattering of a few other items, probably accounting for about a hundred million or so. That would be, I'd call, a corporate items and such that we that across the enterprise. So that should give you the granulate granularity you need. Okay?\n\nNext question, please.\n\nOperator: Our next question comes from Jessica Tassan with Piper Sandler.\n\nJessica Tassan: Hi. Thanks so much for taking the question and for the detail this morning. When we think about the Medicare margin recovery, can you help us understand the split and timing between kind of MLR improvement and then incremental operating leverage, if any, and your updated MA margin targets kind of fully contemplate the benefit of efficiencies you might harvest from AI at UHP. Thanks.\n\nBobby Hunter: Good morning, Jessica. Thanks for the question. So, you know, obviously, when we've outlined the number of actions that we're taking to pursue the margin recovery this morning. They've really been items oriented around what we're doing with optimizing our plan design, ensuring that we're investing in durable and, you know, plans are designed around care management, enabling care management, we've made meaningful benefit adjustments. So all the kind of levers that are in our control related to the product design, operational, cost efficiency is absolutely something that we will continue to drive.\n\nWe are partnered incredibly closely with Sandeep and the team at Optum around different use cases of, you know, how AI can not only drive efficiency, but also help inform the forecast in terms of both kinda how we respond to headwinds or challenges as well as kinda how we identify solutions and can bring those to stakeholders. Think about kind of all of those, you know, really in the mix as we think about opportunities to, you know, leverage those efficiencies, drive margins, and certainly will be supportive of our twenty-seven and beyond, you know, kind of range that I've talked about where we'll be at the midpoint or above in that two to four percent guidance.\n\nStephen Hensley: Okay. We have time for one more question. So please, next.\n\nOperator: And our last question comes from Ben Hendericks with RBC Capital Markets.\n\nBen Hendericks: Great. Thank you for squeezing me in. In light of your business line review and your reorientation of some businesses and balancing that with a sustained commitment to value-based care, I'm wondering if there's any changes to how you're thinking about the breadth and scale of care capabilities that you want to add to support VBC. And specifically, I'm thinking about kind of commitment to assets like the pending meta acquisition and the expected closing there. Thanks.\n\nStephen Hemsley: Sure. Do you want to comment on the MedAssist and then Patrick maybe comment about kind of the broader question there?\n\nJohn Rex: Yeah. Ben, John Rex. Yeah. So we're about looking forward to closing the Amedisys transaction here as we work through the process. We are still working through that process. So as I as I mentioned in my capital comments on the call earlier, I mentioned that's one of the items on our in our in our minds as we think about rest of year. But we continue to work through that process with the regulators. And so productive way.\n\nBut committed to those kind of assets and certainly very committed to capabilities where we can serve people in the home, super important in terms of foundational part of value-based care in terms of how we actually serve them and serve them well. Gives us a lot more reach into serving other people also. And I'll have Patrick maybe comment a bit.\n\nPatrick Conway: Yeah. So thanks for the question, and I'll on the clinical rationale and then pass it off to Chris to hit some clinical operational points. As many of you know, I'm practicing position. It's about patient need. For value-based care, we need clinical assets. We need assets in the home and capabilities and clinicians in the home. We need mental and behavioral. We need specialty care. We need ambulatory surgical centers. You need serious illness care. You need the breadth. We have those component parts in Optum Health. And those allow us to serve people's physical, mental, social, and financial needs. To broaden it out. To Optum Insight as well. That platform for value-based care is distinctive.\n\nIt has huge growth potential as John described earlier and Steve. And importantly, it's a pathway to a better performing US health system. That achieves better health outcomes better experience, and lower cost for the people we serve. I would like Chris to just talk briefly because then you have to execute on that out. On that. You know, with fidelity everywhere about some of the work there.\n\nKrista Nelson: Yeah. Thank you so much for the question. So I think what I'll just add, Patrick, commented a lot on the work we're doing across our value-based care platform to stabilize the business and provide meaningful growth in the future. Maybe just a couple comments on some of the other care delivery services that we offer that really enable that integrated delivery system to come to life. Whether that is you know, investments in ancillary services, whether that's growth in home health, whether that's growth in our ASC platform, those will be things that we consider.\n\nBut most urgently and importantly, the team is really focused on how do we make sure we drive know, the best productivity, the best performance, the best payment yields, and some of the near-term opportunities we have to deliver on our on our services businesses in the short term while we enable further growth for the long term. Thanks for the question.\n\nStephen Hensley: So that's all we have time for today. I would thank you all for joining us. We look forward to speaking with you again in a few months, and I'll find you I think you'll find those to will be even more specific and detailed, but as well a little deeper from a strategic point of view as we continue to progress through our review here and we look forward to those engagements and the engagements with you that we have in the meantime before our next quarterly review. So thank you for joining us. We appreciate your interest and attention. Thanks.\n\nOperator: And ladies and gentlemen, this concludes today's call. Thank you for your participation. You may now disconnect.\n\nPage 1 of 13\nUnitedHealth Group Reports Third Quarter 2025 Results\nand Raises Full Year 2025 Earnings Outlook\n\u2022 Third Quarter 2025 Revenues of $113.2 Billion Grew 12% Year-Over-Year\n\u2022 Third Quarter Earnings of $2.59 Per Share, Adjusted Earnings $2.92 Per Share\n\u2022 Cash Flows from Operations were $5.9 Billion, or 2.3x Net Income\n\u2022 RaisesFull Year 2025 Earnings Outlook to at least $14.90 Per Share; Adjusted Earnings of at least\n$16.25 Per Share\n(October 28, 2025)UnitedHealth Group (NYSE: UNH) reported third quarter 2025 results, reflecting the continued execution\non its performance agenda, refocus on its mission and culture, and return to sustained growth.\n\u201cWe remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond,\nand our results this quarter reflect solid execution toward that goal,\u201d said Stephen Hemsley, chief executive officer of\nUnitedHealth Group.\nUnitedHealth Group raised its 2025 earnings outlook to reflect net earnings of at least $14.90 per share and adjusted net\nearnings of at least $16.25 per share.\nThird Quarter 2025 Key Performance Metrics\n\u2022 Consolidated revenues of $113.2 billion, up 12% year-over-year.\n\u2022 Earnings from operations were $4.3 billion; net margin of 2.1%.\n\u2022 Adjusted EPS of $2.92; GAAP EPS of $2.59.\n\u2022 Medical care ratio (MCR) of 89.9% was in line with expectations outlined in the second quarter 2025.\n\u2022 Operating cost ratio of 13.5% reflecting investments to support future growth.\n\u2022 UnitedHealthcare revenues grew 16% year-over-year to $87.1 billion, driven by growth in Medicare & Retirement and\nCommunity & State; UnitedHealthcare served 50.1 million consumers domestically, up 795,000 year-over-year.\n\u2022 Optum revenues grew 8% year-over-year to $69.2 billion, driven by growth in Optum Rx.\n\u2022 September 30, 2025, debt-to-capital ratio of 44.1% unchanged from the second quarter 2025andinclusive of the impact of\nclosing the Amedisys transaction on August 14, 2025.\nPage 2 of 13\nQuarterly Financial Performance\nThree Months Ended Change From\nSeptember 30,\n2025\nSeptember 30,\n2024\nJune 30,\n2025\nSeptember 30,\n2024\nJune 30,\n2025\nRevenues $113.2 billion $100.8 billion $111.6 billion +12% +1%\nEarnings from Operations $4.3 billion $8.7 billion $5.2 billion -50% -16%\nNet Margin 2.1% 6.0% 3.1% -390bps -100bps\n\u2022 UnitedHealth Group\u2019s third quarter 2025 revenues grew $12.3 billion year-over-year to $113.2 billion.\n\u2022 Third quarter earnings from operations were $4.3 billion and adjusted net earnings were $2.92 per share.\n\u2022 The third quarter consolidated medical care ratio of 89.9% reflected utilization in line with expectations outlined in the\nsecond quarter 2025. The year-over-year increase of 470 basis points was primarily driven by the previously described\nsignificantly elevated cost trends, as well as the ongoing effects of the Biden-era Medicare funding reductions and changes\nto the Part D program from the Inflation Reduction Act. Medical reserve development was $80 million favorable in the\nthird quarter 2025.\n\u2022 Days claims payable of 46.2 compared to 44.5 in the second quarter 2025 and 47.4 in third quarter 2024. Days sales\noutstanding were flat year-over-year at 18.6 and down 1.3 days sequentially.\n\u2022 The third quarter 2025 operating cost ratio of 13.5% compared to 13.2% in the year ago quarter.\n\u2022 Cash flows from operations were $5.9 billion in the third quarter 2025, or 2.3x net income. \nPage 3 of 13\nUnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid\nbeneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and\nwellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.\nQuarterly Financial Performance\nThree Months Ended Change From\nSeptember 30,\n2025\nSeptember 30,\n2024\nJune 30,\n2025\nSeptember 30,\n2024\nJune 30,\n2025\nRevenues $87.1 billion $74.9 billion $86.1 billion +16% +1%\nEarnings from Operations $1.8 billion $4.2 billion $2.1 billion -57% -13%\nOperating Margin 2.1% 5.6% 2.4% -350bps -30bps\nUnitedHealthcare\n\u2022 UnitedHealthcare\u2019s third quarter 2025 revenues of $87.1 billion grew $12.2 billion or 16% year-over-year.\nUnitedHealthcare served 50.1 million people domestically in the third quarter 2025, an increase of 795,000 year-over-year.\n\u2022 UnitedHealthcare\u2019s third quarter 2025 earnings from operations were $1.8 billion compared to $4.2 billion in third quarter\n2024. Third quarter 2025 operating margin of 2.1% compared to 5.6% in third quarter 2024, primarily due to elevated\nmedical cost trend, the effects of the Biden-era Medicare funding reductions and Part D IRA impacts.\nUnitedHealthcare Employer & Individual\n\u2022 UnitedHealthcare Employer & Individual third quarter 2025 revenues were $19.9 billion compared to $19.8 billion in third\nquarter 2024.\n\u2022 The number of people served domestically increased by 200,000 year-over-year, with growth in employer self-funded\nofferings of 660,000 partially offset by attrition in both group fully-insured and individual products.\nUnitedHealthcare Medicare & Retirement\n\u2022 UnitedHealthcare Medicare & Retirement third quarter 2025 revenues of $43.4 billion grew $8.5 billion or 24% year-overyear due to growth in the number of people served and the effects of the Part D IRA impacts.\n\u2022 People served with individual and group Medicare Advantage offerings grew 85,000 in the third quarter 2025 and 625,000\nyear-over-year.\nUnitedHealthcare Community & State\n\u2022 UnitedHealthcare Community & State third quarter 2025 revenues of $23.8 billion grew 18% year-over-year, driven by\ngrowth in serving people with complex needs and Medicaid rate improvements.\n\u2022 Members served contracted by 30,000 in the third quarter 2025. \nPage 4 of 13\nThe Optum health services businesses serve the global health care marketplace, including payers, care providers, employers,\ngovernments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield\nclinical insights, Optum helps improve overall health system performance by optimizing care quality, reducing care costs and\nimproving the consumer experience.\nQuarterly Financial Performance\nThree Months Ended Change From\nSeptember 30,\n2025\nSeptember 30,\n2024\nJune 30,\n2025\nSeptember 30,\n2024\nJune 30,\n2025\nRevenues $69.2 billion $63.9 billion $67.2 billion +8% +3%\nEarnings from Operations $2.5 billion $4.5 billion $3.1 billion -44% -18%\nOperating Margin 3.6% 7.0% 4.6% -340bps -100bps\nOptum Health\n\u2022 Optum Health\u2019s third quarter 2025 revenues of $25.9 billion were flat year-over-year.\n\u2022 Third quarter 2025 earnings from operations were $255 million, reflecting an operating margin of 1%. This compares to\noperating earnings of $2.2 billion and an operating margin of 8.3% in the third quarter 2024. The year-over-year decline\nwas driven by continued reimbursement pressure due to the Medicare funding reductions and elevated utilization and costs.\nOptum Insight\n\u2022 Optum Insight\u2019s third quarter 2025 revenues of $4.9 billion were flat year-over-year.\n\u2022 Third quarter 2025 earnings from operations were $706 million compared to $791 million a year ago and operating\nmargins were 14.4% and 16.0%, respectively, due to investments to support future growth. The contract revenue backlog\nwas $32.1 billion.\nOptum Rx\n\u2022 Optum Rx\u2019s third quarter 2025 revenues of $39.7 billion increased 16% year-over-year driven by growth in script volumes\nfrom new clients and growth in existing clients, as well as growth in pharmacy services.\n\u2022 Earnings from operations for third quarter 2025 were $1.5 billion compared to $1.5 billion a year ago and operating\nmargins were 3.9% and 4.5%, respectively. The operating margin decline year-over-year was primarily due to the mix\neffects of higher cost drugs driving higher revenue growth in the third quarter 2025 but with lower margins. Adjusted\nscripts grew to 414 million, up from 407 million last year.\nPage 5 of 13\nAbout UnitedHealth Group\nUnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives\nand help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers\ncare aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve\nbetter health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care\nexperience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow\nUnitedHealth Group on LinkedIn.\nEarnings Conference Call\nAs previously announced, UnitedHealth Group will discuss the company\u2019s results, strategy and future outlook on a conference\ncall with investors at 8:00 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from\nthe Investor Relations page of the company\u2019s website (www.unitedhealthgroup.com). Following the call, a webcast replay will\nbe on the Investor Relations page through November 11, 2025. This earnings release and the Form 8-K dated October 28, 2025,\ncan also be accessed from the Investor Relations page of the company\u2019s website.\nNon-GAAP Financial Information\nThis news release presents non-GAAP financial information provided as a complement to the results provided in accordance\nwith accounting principles generally accepted in the United States of America (\u201cGAAP\u201d). A reconciliation of the non-GAAP\nfinancial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at\nthe end of this release.\nForward-Looking Statements\nThe statements, estimates, projections, guidance or outlook contained in this document include \u201cforward-looking\u201d statements\nwhich are intended to take advantage of the \u201csafe harbor\u201d provisions of the federal securities laws. The words \u201cbelieve,\u201d\n\u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d and similar expressions identify\nforward-looking statements. These statements may contain information about financial prospects, economic conditions and\ntrends and involve risks and uncertainties. Actual results could differ materially from those that management expects,\ndepending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs;\nnew or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data\nsecurity incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received\nunder government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data\nvalidation audits; the DOJ\u2019s legal actions concerning our participation in the Medicare program; our ability to maintain and\nachieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if\nour technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy\ncare services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to\nour public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and\nmaintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of\npotential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government\ninvestigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties\nassociated with the sale of our remaining operations in South America; risks associated with public health crises arising from\nlarge-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and\nmanage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill\nand intangible assets; failure to protect proprietaryrights to our databases, software and related products; downgrades in our\ncredit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our\nobligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend\npayment cycle, or continue repurchasing shares of our common stock.\nThis above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial\ncondition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.\nBy their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,\nuncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations\nexpressed or implied in this document or any of our prior communications. You should not place undue reliance on forwardlooking statements, which speak only as of the date they are made. We do not undertake to update or revise any forwardlooking statements, except as required by law.\nInvestors: Media:\ninvestor_relations@uhg.com uhgmedia@uhg.com\nUNITEDHEALTH GROUP\nEarnings Release Schedules and Supplementary Information\nQuarter Ended September 30, 2025\n\n\u2022 Condensed Consolidated Statements of Operations\n\u2022 Condensed Consolidated Balance Sheets\n\u2022 Condensed Consolidated Statements of Cash Flows\n\u2022 Supplemental Financial Information - Businesses\n\u2022 Supplemental Financial Information - People Served and Performance Metrics\n\u2022 Reconciliation of Non-GAAP Financial Measure\nPage 6 of 13\nUNITEDHEALTH GROUP\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n(in millions, except per share data; unaudited)\nThree Months Ended\nSeptember 30,\nNine Months Ended\nSeptember 30,\n2025 2024 2025 2024\nRevenues\nPremiums ........................................................................................................................ $88,979 $77,442 $263,418 $232,327\nProducts........................................................................................................................... 13,296 12,631 39,896 36,751\nServices ........................................................................................................................... 9,754 9,104 27,765 26,742\nInvestment and other income....................................................................................... 1,132 1,643 3,273 3,651\n Total revenues........................................................................................................... 113,161 100,820 334,352 299,471\nOperating costs\nMedical costs .................................................................................................................. 79,958 65,957 231,954 197,150\nOperating costs .............................................................................................................. 15,223 13,280 42,595 40,519\nCost of products sold..................................................................................................... 12,566 11,834 37,975 34,230\nDepreciation and amortization..................................................................................... 1,099 1,041 3,244 3,058\n Total operating costs ................................................................................................ 108,846 92,112 315,768 274,957\nEarnings from operations.......................................................................................... 4,315 8,708 18,584 24,514\nInterest expense............................................................................................................. (1,003) (1,074) (3,028) (2,903)\nLoss on sale of subsidiary and subsidiaries held for sale........................................ (83) (20) (139) (8,331)\nEarnings before income taxes.................................................................................. 3,229 7,614 15,417 13,280\nProvision for income taxes............................................................................................ (686) (1,356) (2,828) (3,822)\nNet earnings.................................................................................................................. 2,543 6,258 12,589 9,458\nEarnings attributable to noncontrolling interests ....................................................... (195) (203) (543) (596)\nNet earnings attributable to UnitedHealth Group common shareholders.... $2,348 $6,055 $12,046 $8,862\nDiluted earnings per share attributable to UnitedHealth Group common\nshareholders ......................................................................................................... $2.59 $6.51 $13.21 $9.53\nAdjusted earnings per share attributable to UnitedHealth Group common\nshareholders (a).................................................................................................... $2.92 $7.15 $14.22 $20.85\nDiluted weighted-average common shares outstanding.......................................... 908 930 912 930\n(a) See page 12 for a reconciliation of the non-GAAP measure.\nPage 7 of 13\nUNITEDHEALTH GROUP\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in millions; unaudited)\nSeptember 30,\n2025\nDecember 31,\n2024\nAssets\nCash and short-term investments ..................................................................................................................................................... $30,614 $29,113\nAccounts receivable, net .................................................................................................................................................................... 22,672 22,365\nOther current assets............................................................................................................................................................................ 41,781 34,301\nTotal current assets................................................................................................................................................................... 95,067 85,779\nLong-term investments ....................................................................................................................................................................... 52,996 52,354\nOther long-term assets ....................................................................................................................................................................... 167,206 160,145\nTotal assets.................................................................................................................................................................................... $315,269 $298,278\nLiabilities, redeemable noncontrolling interests and equity\nMedical costs payable......................................................................................................................................................................... $40,181 $34,224\nShort-term borrowings and current maturities of long-term debt................................................................................................. 7,737 4,545\nOther current liabilities ........................................................................................................................................................................ 67,608 65,000\nTotal current liabilities............................................................................................................................................................... 115,526 103,769\nLong-term debt, less current maturities............................................................................................................................................ 72,399 72,359\nOther long-term liabilities.................................................................................................................................................................... 21,531 19,559\nRedeemable noncontrolling interests ............................................................................................................................................... 4,244 4,323\nEquity..................................................................................................................................................................................................... 101,569 98,268\nTotal liabilities, redeemable noncontrolling interests and equity........................................................................................... $315,269 $298,278\nPage 8 of 13\nUNITEDHEALTH GROUP\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in millions; unaudited)\nNine Months Ended\nSeptember 30,\n2025 2024\nOperating Activities\nNet earnings ......................................................................................................................................................................................... $12,589 $9,458\nNoncash items:\nDepreciation and amortization....................................................................................................................................................... 3,244 3,058\nDeferred income taxes and other.................................................................................................................................................. (955) (844)\nShare-based compensation ........................................................................................................................................................... 795 831\nLoss on sale of subsidiary and subsidiaries held for sale.......................................................................................................... 139 8,331\nNet changes in operating assets and liabilities............................................................................................................................... 2,777 1,001\nCash flows from operating activities.......................................................................................................................................... 18,589 21,835\nInvesting Activities\nSales and maturities of investments, net of purchases ................................................................................................................. 1,657 1,852\nPurchases of property, equipment and capitalized software........................................................................................................ (2,674) (2,587)\nCash paid for acquisitions and other transactions, net.................................................................................................................. (4,436) (11,674)\nLoans to care providers - cyberattack .............................................................................................................................................. \u2014 (8,904)\nRepayments of care provider loans - cyberattack.......................................................................................................................... 1,543 3,189\nOther, net .............................................................................................................................................................................................. (2,164) (1,284)\nCash flows used for investing activities .................................................................................................................................... (6,074) (19,408)\nFinancing Activities\nCommon share repurchases.............................................................................................................................................................. (5,545) (4,028)\nDividends paid...................................................................................................................................................................................... (5,914) (5,601)\nNet change in short-term borrowings and long-term debt............................................................................................................. 2,438 15,120\nOther, net .............................................................................................................................................................................................. (1,592) (661)\nCash flows (used for) from financing activities ........................................................................................................................ (10,613) 4,830\nEffect of exchange rate changes on cash and cash equivalents................................................................................................. 25 (30)\nIncrease in cash and cash equivalents, including cash within businesses held for sale......................................................... 1,927 7,227\nLess: net increase in cash within businesses held for sale .......................................................................................................... (29) (254)\nNet increase in cash and cash equivalents ..................................................................................................................................... 1,898 6,973\nCash and cash equivalents, beginning of period............................................................................................................................ 25,312 25,427\nCash and cash equivalents, end of period ...................................................................................................................................... $27,210 $32,400\nPage 9 of 13\nUNITEDHEALTH GROUP\nSUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES\n(in millions, except percentages)\n(unaudited)\nThree Months Ended\nSeptember 30,\nNine Months Ended\nSeptember 30,\n2025 2024 2025 2024\nRevenues\nUnitedHealthcare............................................................................................................ $87,070 $74,853 $257,790 $224,076\nOptum ............................................................................................................................... 69,177 63,925 200,287 187,856\nEliminations...................................................................................................................... (43,086) (37,958) (123,725) (112,461)\nTotal consolidated revenues................................................................................... $113,161 $100,820 $334,352 $299,471\nEarnings from Operations\nUnitedHealthcare............................................................................................................ $1,805 $4,212 $9,106 $12,611\nOptum (a) ......................................................................................................................... 2,510 4,496 9,478 11,903\nTotal consolidated earnings from operations....................................................... $4,315 $8,708 $18,584 $24,514\nOperating Margin\nUnitedHealthcare............................................................................................................ 2.1% 5.6% 3.5% 5.6%\nOptum ............................................................................................................................... 3.6% 7.0% 4.7% 6.3%\nConsolidated operating margin.............................................................................. 3.8% 8.6% 5.6% 8.2%\nRevenues\nUnitedHealthcare Employer & Individual - Domestic ................................................ $19,049 $18,985 $57,065 $55,470\nUnitedHealthcare Employer & Individual - Global...................................................... 826 769 2,427 2,892\nUnitedHealthcare Employer & Individual - Total.................................................. 19,875 19,754 59,492 58,362\nUnitedHealthcare Medicare & Retirement.................................................................. 43,356 34,904 127,684 105,294\nUnitedHealthcare Community & State......................................................................... 23,839 20,195 70,614 60,420\nOptum Health................................................................................................................... $25,900 $25,917 $76,414 $79,698\nOptum Insight.................................................................................................................. 4,915 4,931 14,373 13,976\nOptum Rx ......................................................................................................................... 39,679 34,207 113,270 97,457\nOptum eliminations ......................................................................................................... (1,317) (1,130) (3,770) (3,275)\n(a) Earnings from operations for Optum for the three and nine months ended September 30, 2025 included $255 and $2,505 for Optum Health; $706 and $2,665 for\nOptum Insight; and $1,549 and $4,308 for Optum Rx, respectively. Earnings from operations for Optum for the three and nine months ended September 30, 2024\nincluded $2,161 and $5,979 for Optum Health; $791 and $1,827 for Optum Insight; and $1,544 and $4,097 for Optum Rx, respectively.\nPage 10 of 13\nUNITEDHEALTH GROUP\nSUPPLEMENTAL FINANCIAL INFORMATION - PEOPLE SERVED AND PERFORMANCE METRICS\n(unaudited)\nUnitedHealthcare Customer Profile\n(in thousands)\nPeople Served September 30, 2025 June 30, 2025 December 31, 2024 September 30, 2024\nCommercial:\nRisk-based...................................................................................... 8,440 8,440 8,845 8,900\nFee-based....................................................................................... 21,490 21,530 20,885 20,830\n Total Commercial......................................................................... 29,930 29,970 29,730 29,730\nMedicare Advantage.......................................................................... 8,435 8,350 7,845 7,810\nMedicaid............................................................................................... 7,460 7,490 7,435 7,450\nMedicare Supplement (Standardized)............................................. 4,300 4,305 4,335 4,340\n Total Community and Senior................................................... 20,195 20,145 19,615 19,600\n Total UnitedHealthcare - Medical............................................ 50,125 50,115 49,345 49,330\nSupplemental Data\nMedicare Part D stand-alone....................................................... 2,795 2,800 3,050 3,055\nSouth American businesses held for sale................................. 1,160 1,165 1,330 1,335\nOptum Performance Metrics\nSeptember 30, 2025 June 30, 2025 December 31, 2024 September 30, 2024\nOptum Health Consumers Served (in millions) ............................. 96 98 100 104\nOptum Insight Contract Backlog (in billions).................................. $32.1 $32.1 $32.8 $32.8\nOptum Rx Quarterly Adjusted Scripts (in millions)........................ 414 414 422 407\nPage 11 of 13\nUNITEDHEALTH GROUP\nRECONCILIATION OF NON-GAAP FINANCIAL MEASURE\nUse of Non-GAAP Financial Measure\nAdjusted net earnings per share is a non-GAAP financial measure. Non-GAAP financial measures should be considered in addition to, but not as a\nsubstitute for, or superior to, financial measures prepared in accordance with GAAP. Adjustments to adjusted net earnings per share are as follows:\nIntangible Amortization: As amortization fluctuates based on the size and timing of the company\u2019s acquisition activity, management believes this exclusion\nprovides a more useful comparison of the company\u2019s underlying business performance and trends from period to period. While intangible assets contribute\nto the Company\u2019s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings\nper share.\nSouth American Impacts: The loss on the sale of our Brazilian operations completed on February 6, 2024, the loss on our remaining South American\noperations being classified as held for sale and certain other non-recurring matters impacting our South American operations are not representative of the\nCompany\u2019s underlying business performance and therefore management believes the exclusion presents a more useful comparison of the Company\u2019s\nunderlying business performance and trends from period to period.\nDirect Response Costs - Cyberattack: Management believes the exclusion of costs incurred to investigate and remediate the attack, other direct and\nincremental costs incurred as a result of the cyberattack and incremental costs for accommodations to support care providers presents a more useful\ncomparison of the Company\u2019s underlying business performance and trends from period to period.\nPage 12 of 13\nUNITEDHEALTH GROUP\nRECONCILIATION OF NON-GAAP FINANCIAL MEASURE\n(in millions, except per share data; unaudited)\nAdjusted Net Earnings Per Share\nThree Months Ended\nSeptember 30,\nNine Months Ended\nSeptember 30,\nProjected Year Ended\nDecember 31,\n2025 2024 2025 2024 2025 (e)\nNet earnings attributable to UnitedHealth Group common shareholders ............ $2,348 $6,055 $12,046 $8,862 At least $13,600\nIntangible amortization, net of tax (a) ........................................................................ 302 322 927 937 ~1,225\nSouth American impacts, net of tax (c)...................................................................... \u2014 13 \u2014 8,282 \u2014\nDirect response costs - cyberattack, net of tax (d).................................................. \u2014 261 \u2014 1,307 \u2014\nAdjusted net earnings attributable to UnitedHealth Group common\nshareholders.................................................................................................... $2,650 $6,651 $12,973 $19,388 At least $14,825\nDiluted earnings per share.......................................................................................... $2.59 $6.51 $13.21 $9.53 At least $14.90\nIntangible amortization, net of tax, per share (b)..................................................... 0.33 0.35 1.01 1.01 ~1.35\nSouth American impacts, net of tax, per share (c)................................................... \u2014 0.01 \u2014 8.90 \u2014\nDirect response costs - cyberattack, net of tax, per share (d)............................... \u2014 0.28 \u2014 1.41 \u2014\nAdjusted diluted earnings per share................................................................... $2.92 $7.15 $14.22 $20.85 At least $16.25\n(a) Intangible amortization for the three months ended September 30, 2025 and 2024 was $401 and $426, with tax effects of $(99) and $(104), respectively. Intangible\namortization for the nine months ended September 30, 2025 and 2024 was $1,227 and $1,242, with tax effects of $(300) and $(305), respectively. For the projected\nyear ended December 31, 2025 intangible amortization is ~$1,625, with tax effects of ~$(400).\n(b) Intangible amortization per share for the three months ended September 30, 2025 and 2024 was $0.44 and $0.46, with tax effects of $(0.11) and $(0.11), respectively.\nIntangible amortization per share for the nine months ended September 30, 2025 and 2024 was $1.34 with tax effects of $(0.33). For the projected year ended\nDecember 31, 2025 intangible amortization per share is ~$1.75, with tax effects of ~$(0.40).\n(c) South American impacts for the three months ended September 30, 2024 and nine months ended September 30, 2024 were $9 and $8,435, with tax effects of $4 and\n$(153), respectively. South American impacts per share for the three months ended September 30, 2024 and nine months ended September 30, 2024 were $0.01 and\n$9.07, with tax effects of $0.00 and $(0.17), respectively.\n(d) Direct response costs - cyberattack for the three months ended September 30, 2024 and nine months ended September 30, 2024 were $341 and $1,710, with tax effects\nof $(80) and $(403), respectively. Direct response costs - cyberattack per share for the three months ended September 30, 2024 and nine months ended September 30,\n2024 were $0.37 and $1.84, with tax effects of $(0.09) and $(0.43), respectively.\n(e) Projected year ended December 31, 2025 net earnings attributable to UnitedHealth Group common shareholders and diluted earnings per share do not contemplate the\npotential impacts of any actions that may occur in the fourth quarter related to our on-going business assessment plans.\nPage 13 of 13\n\n"
    }
  ],
  "rubrics": [
    "The response should begin by identifying the current reporting period as Q3 2025.",
    "The response should identify the Q2 2025 10-Q filing.",
    "The response should identify the Q2 earnings call transcript.",
    "The response should provide a numbered list of exactly 8 high-priority questions based on the provided content suitable for a live earnings call.",
    "The response should group the questions by theme. For example, Strategy and Medical Costs.",
    "The response should clearly identify each theme by using a headline. For example, Theme 1: Optum Health Strategy.",
    "The response should include a \"Why it matters\" section for each question.",
    "The response should limit the \"Why it matters\" section of each question to 1 or 2 lines only.",
    "The response should compose it's questions based on the provided source material only. For example, it should not rely on outside knowledge of company performance.",
    "The response should maintain a professional and concise structure. For example, it should use precise headlines and bullet points.",
    "The response should include an exact source or citation when any data or numerical figures are used. For example, \"Q2 Earnings Call Transcript, pg. 12.\"."
  ],
  "metadata": {
    "task_id": "2f52c47e-3cf1-4712-8840-1338c93fd9d1",
    "context_id": "4b734420-7555-4b08-83c3-005c0421cf00",
    "context_category": "Domain Knowledge Reasoning",
    "sub_category": "Finance"
  }
}